Amorphous kinase inhibitor formulations and methods of use thereof

Abstract

To provide broad-spectrum c-KIT inhibitors, and stable oral formulations thereof.SOLUTION: A pharmaceutically acceptable composition for oral administration comprises: (i) a solid dispersion comprising an amorphous form of a compound represented by Formula (I) in the figure, and a pharmaceutically acceptable polymer; and (ii) one or more pharmaceutically acceptable fillers. The amorphous compound is useful in treatment of disorders related to the activity of the c-KIT and PDGFRα kinases and of oncogenic forms thereof.SELECTED DRAWING: None

Description

[Technical field]

[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims priority to USSN 62 / 955,073, filed December 30, 2019, USSN 62 / 955,062, filed December 30, 2019, USSN 62 / 968,695, filed January 31, 2020, and USSN 62 / 968,724, filed January 31, 2020, the contents of each of which are incorporated herein by reference in their entirety. [Background technology]

[0002] c-KIT (also known as KIT, CD117, and stem cell factor receptor) is a 145 kDa transmembrane tyrosine kinase protein that acts as a type III receptor. The c-KIT proto-oncogene, located on chromosome 4q11-21, encodes the c-KIT receptor, whose ligands are stem cell factor (SCF), hematopoietic stem cell factor, kit ligand, and mast cell growth factor). The receptor has tyrosine protein kinase activity, and binding of the ligand SCF leads to the autophosphorylation of c-KIT and its association with substrates such as phosphatidylinositol 3-kinase (PI3K). Tyrosine phosphorylation by protein tyrosine kinases is particularly important in cell signaling and can mediate signals for key intracellular processes such as proliferation, survival, differentiation, apoptosis, adhesion, invasion, and migration. Deficiency of c-KIT is the cause of focal albinism, an autosomal dominant developmental abnormality of pigmentation characterized by congenital patches of white skin and hair lacking melanocytes. Gain-of-function mutations in the c-KIT gene and expression of constitutively phosphorylated c-KIT are found in most gastrointestinal stromal tumors (GISTs) and mastocytosis. In addition, nearly all gonadal seminomas / dysgerminomas exhibit c-KIT membrane staining, and several reports have clarified that a proportion (10–25%) harbor c-KIT gene mutations. c-KIT deficiency has also been associated with testicular tumors, including germ cell tumors (GCTs) and testicular germ cell tumors (TGCTs). C-KIT mutations have also been associated with a subgroup of cutaneous or acral melanomas.

[0003] Oncogenic genomic alterations in PDGFRα kinase or overexpression of PDGFRα kinase have been shown to be causative in human cancers. Missense mutations in PDGFRα kinase have also been shown to be causative in a subgroup of GISTs. PDGFRα mutations are the inducing factor in oncogenesis in approximately 8–10% of GISTs. The dominant mutation in PDGFRα is exon 18 D842V, but other exon 18 mutations including D846Y, N848K, and Y849K, as well as exon 18 insertion-deletion mutations (indels) including RD841-842KI, DI842-843-IM, and HDSN845-848P, have also been reported. In addition, rare mutations in exons 12 and 14 of PDGFRα have also been reported. PDGFRα exon 18 deletion mutations ΔD842-H845 and ΔI843-D846 have been reported in GISTs. PDGRFα amplification or mutations have also been reported in human tissues with malignant peripheral nerve sheath tumors (MPNSTs). PDGFRα amplification has been reported in multiple cutaneous lesions of undifferentiated pleomorphic sarcoma and in intimal sarcomas. PDGFRα amplification has been linked to a subset of lung cancer patients. 4q12, which contains the PDGFRα locus, is amplified in 3-7% of lung adenocarcinomas and 8-10% of lung squamous cell carcinomas. PDGFRα amplification is universal in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1-mutated glioblastomas. PDGFRα amplification was frequent in pediatric (29.3%) and adult (20.9%) tumors. PDGFRα amplification was associated with increased grade and, notably, poor prognosis in IDH1-mutated de novo GBM. It has been reported that the PDGFRα locus in this PDGFRα-amplified glioma has been shown to exhibit an intragenic deletion rearrangement of exons 8 and 9 of PDGFRα. This intragenic deletion is ubiquitous and is present in 40% of glioblastoma multiforme (GBM) cases that exhibit PDGFRα amplification. Tumors with this rearrangement exhibit histological characteristics of oligodendroglioma, and the intragenic deletion of PDGFRα exons 8 and 9 shows elevated constitutive tyrosine kinase activity. The FIP1L1-PDGFRA fusion protein is oncogenic in a subgroup of patients with hypereosinophilic syndrome. The FIP1L1-PDGFRα fusion has also been identified in eosinophilic acute myeloid leukemia, and lymphoblastic T-cell lymphoma.

[0004] Such broad-spectrum c-KIT inhibitors and their formulations would be of high therapeutic value in the treatment of patients with refractory GIST and other disorders. There is a need for oral formulations that provide patients with a significantly more stable product. Mutations, deletions, rearrangements and amplifications of the PDGFRα gene have been associated with many solid and hematological cancers. Given the complex function of the PDGFRα gene and the potential utility of PDGFRα inhibitors in the treatment of various solid and hematological cancers, there is a need for oral formulations of the inhibitor with good therapeutic performance. Summary of the Invention

[0005] Provided herein, in part, are amorphous forms of the compound of Formula (I), solid dispersions, and pharmaceutical compositions comprising the amorphous form of the compound of Formula (I), suitable for oral administration comprising the amorphous form of the compound of Formula (I). [ka] For example, provided herein is a pharmaceutical composition comprising a solid spray-dried dispersion comprising an amorphous form of a compound represented by formula (I) and a pharma- ceutically acceptable polymer and one or more pharma- ceutically acceptable carriers. Contemplated compositions provided herein, including an amorphous form of formula I, such as the solid dispersions described herein, may, in certain embodiments, provide an enhanced pharmacokinetic profile when administered to a patient, for example, compared to administration of a crystalline form of formula I. The disclosed compositions (e.g., tablets), in at least some embodiments, may provide a fast release (e.g., within 30 minutes) and / or fast dissolution of formula I.

[0006] Also provided herein in one embodiment is a pharmaceutical composition comprising: (a) an intragranular blend comprising: (i) a solid dispersion comprising an amorphous form of a compound represented by Formula (I) and a pharma- ceutically acceptable polymer, (ii) one or more fillers, (iii) a disintegrant, (iv) a glidant, and (v) a lubricant; and (b) an extragranular blend comprising: (i) a glidant, and (ii) a lubricant.

[0007] In some embodiments, provided herein are amorphous forms of compounds of formula (I) that are free of detectable amounts of any crystalline form.

[0008] In some embodiments, the present disclosure provides a compound of formula (I) in a detectable amount in any crystalline form. A compound-free amorphous form of the compound of formula (I) is provided.

[0009] In some embodiments, provided herein is an amorphous form of the compound of formula (I), comprising no more than about 5% (w / w) of the compound of formula (I) in any crystalline form.

[0010] Also provided herein, in one embodiment, is an amorphous form of the compound of formula (I), comprising no more than about 5% (w / w) of any crystalline form, or any detectable amount of the compound of formula (I), when exposed to 0-100% relative humidity at 25° C.-40° C. for at least 3 months.

[0011] Also provided herein, in one embodiment, is a compound of formula (I), wherein the compound is greater than about 95% amorphous. In some embodiments, the compound of formula (I), wherein the compound is greater than about 95% amorphous by PXRD analysis.

[0012] In one embodiment, there is also provided herein a compound of formula (I) in amorphous form, substantially free of any other crystalline forms of the compound of formula (I).

[0013] Also provided herein, in one embodiment, is a compound of formula (I) in amorphous form essentially free of crystalline material having a purity of at least about 95%, excluding residual solvent.

[0014] Also provided herein, in one embodiment, is a pharmaceutical composition comprising an amorphous form of a compound of formula (I) having a purity by HPLC of greater than 95% and one or more pharma- ceutically acceptable carriers, excipients, or diluents.

[0015] Also provided herein, in one embodiment, is a pharmaceutical composition comprising an amorphous form of a compound of Formula (I), free of any detectable amount of crystalline form, and one or more pharma- ceutically acceptable carriers, excipients, or diluents.

[0016] In some embodiments, also provided herein are pharmaceutical compositions comprising an amorphous form of the compound of formula (I), free of any detectable amount of crystalline form of the compound of formula (I), and one or more pharma- ceutically acceptable carriers, excipients, or diluents.

[0017] In some embodiments, provided herein are pharmaceutical compositions comprising an amorphous form of the compound of formula (I) having no more than about 5% (w / w) of the compound of formula (I) in any crystalline form, and one or more pharma- ceutically acceptable carriers, excipients, or diluents.

[0018] Also provided herein, in one embodiment, is a pharmaceutical composition comprising an amorphous form of the compound of formula (I), comprising no more than about 5% (w / w) of any crystalline form, or any detectable amount of the compound of formula (I), when exposed to 0-100% relative humidity at 25° C.-40° C. for at least about three months, and one or more pharma- ceutically acceptable carriers, excipients, or diluents.

[0019] Also provided herein, in one embodiment, is a pharmaceutical composition comprising an amorphous form of a compound of formula (I), wherein the compound is greater than about 95% amorphous, and one or more pharma- ceutically acceptable carriers, excipients, or diluents. In some embodiments, the pharmaceutical composition comprises a compound of formula (I), wherein the compound is greater than about 95% amorphous by PXRD analysis.

[0020] In one embodiment, the present disclosure also provides a compound of the formula ( Also provided is a pharmaceutical composition comprising an amorphous form of the compound of formula I) and one or more pharma- ceutically acceptable carriers, excipients, or diluents.

[0021] Also provided herein, in one embodiment, is a pharmaceutical composition comprising an amorphous form of a compound of formula (I) substantially free of crystalline form, having a purity of at least about 95% by HPLC, excluding residual solvent, and one or more pharma- ceutically acceptable carriers, excipients, or diluents.

[0022] Also provided herein, in one embodiment, is a solid dispersion comprising an amorphous form of the compound of formula (I) having a purity of greater than 95% by HPLC and a polymer in admixture with one or more pharma- ceutically acceptable carriers, excipients or diluents.

[0023] Also provided herein, in an embodiment, is an amorphous form of a solid dispersion comprising a compound of Formula (I) and a pharma- ceutically acceptable polymer, e.g., hydroxypropylmethylcellulose acetate succinate, wherein the amorphous form is characterized by a powder X-ray diffraction having broad peaks at 2θ degrees, e.g., broad peaks at about 9.5 and about 17 to about 29 2θ degrees. In some embodiments, the amorphous form of the compound of Formula (I) is characterized by an X-ray diffraction pattern substantially as shown in FIG.

[0024] Also provided herein, in one embodiment, is a solid dispersion comprising an amorphous form of a compound of formula (I), free of any detectable amount of crystalline form, and one or more pharma- ceutically acceptable carriers, excipients, or diluents.

[0025] In some embodiments, provided herein is a solid dispersion comprising an amorphous form of the compound of formula (I) having no detectable amount relative to any crystalline form of the compound of formula (I) and a polymer in admixture with one or more pharma- ceutically acceptable carriers, excipients, or diluents.

[0026] Also provided herein, in one embodiment, is a solid dispersion comprising an amorphous form of a compound of formula (I), having no more than about 5% (w / w) of any crystalline form for the compound of formula (I), and a polymer in admixture with one or more pharma- ceutically acceptable carriers, excipients or diluents.

[0027] Also provided herein, in one embodiment, is a solid dispersion comprising an amorphous form of the compound of formula (I) containing no more than about 5% (w / w) of any crystalline form, or any detectable amount of the compound of formula (I) in any crystalline form, when exposed to 0-100% relative humidity at 25° C.-40° C. for about 3 months, and a polymer in admixture with one or more pharma- ceutically acceptable carriers, excipients or diluents.

[0028] Also provided herein, in one embodiment, is a solid dispersion comprising an amorphous form of a compound of formula (I), wherein the compound is greater than about 95% amorphous, and a polymer in admixture with one or more pharma- ceutically acceptable carriers, excipients, or diluents.

[0029] Also provided herein, in one embodiment, is a solid dispersion comprising an amorphous form of the compound of formula (I), substantially free of any other crystalline form, and a polymer in admixture with one or more pharma- ceutically acceptable carriers, excipients, or diluents.

[0030] Also provided herein in one embodiment is a method for preparing a pharmaceutical composition comprising an amorphous form of a compound of formula (I) substantially free of crystalline form having a purity of at least about 95% by HPLC, excluding residual solvent, and a polymer in admixture with one or more pharma- ceutically acceptable carriers, excipients, or diluents. Solid dispersions have also been provided.

[0031] In one embodiment, provided herein is a pharma- ceutically acceptable composition for oral administration, the composition comprising: (i) a solid dispersion, the solid dispersion comprising an amorphous form of a compound represented by formula (I): [ka] and a pharma- ceutically acceptable polymer; and (ii) one or more pharma-ceutically acceptable excipients.

[0032] In another embodiment, the present specification provides a compound represented by formula (I): [ka] and a pharma- ceutically acceptable excipient, wherein greater than about 96% by weight of the compound present in the pharma- ceutically acceptable composition is in amorphous form.

[0033] In another embodiment, described herein is a pharma- ceutically acceptable composition for orally delivering 50 mg of a compound represented by formula (I) to a patient, [ka] This includes an intragranular blend, the intragranular blend comprising a solid dispersion having 50 mg of a compound, the compound being present in amorphous form (hydroxypropylmethylcellulose acetate succinate), an intragranular blend comprising a bulking agent and / or filler, a lubricant and / or glidant, and an extragranular blend comprising a lubricant and / or glidant.

[0034] In another embodiment, the present disclosure provides a method of administering 50 mg of a compound represented by formula (I) to a patient. A pharma- ceutically acceptable composition for oral delivery to is described, [ka] This includes a solid dispersion having 50 mg of a compound, where the compound is present in amorphous form, hydroxypropyl methylcellulose acetate succinate, a bulking agent, filler, and a lubricant and / or glidant.

[0035] In another embodiment, described herein is a pharma- ceutically acceptable tablet having 50 mg of a compound represented by formula (I), [ka] It comprises an intragranular blend, the intragranular blend comprising a solid dispersion having 50 mg of a compound, the compound being present in amorphous form, which is hydroxypropyl methylcellulose acetate succinate, about 25-35% by weight of a bulking agent based on the total weight of the drug composition, about 25-35% by weight of a filler based on the total weight of the drug composition, and an extragranular blend comprising a glidant and / or a lubricant.

[0036] In another embodiment, described herein is a pharma- ceutically acceptable tablet having 50 mg of a compound represented by formula (I), [ka] wherein the tablet comprises a solid dispersion having 50 mg of a compound, wherein the compound is present in amorphous form, the solid dispersion being hydroxypropyl methylcellulose acetate succinate, about 25-35% by weight of microcrystalline cellulose, based on the total weight of the tablet, and about 25-35% by weight of lactose or its hydrate, based on the total weight of the pharmaceutical composition.

[0037] In another embodiment, described herein is a pharma- ceutically acceptable composition for orally delivering 50 mg of a compound represented by formula (I), [ka] This includes an intragranular blend, the intragranular blend comprising a solid dispersion having 50 mg of a compound, the compound being present in amorphous form, the solid dispersion being hydroxypropyl methylcellulose acetate succinate, an intragranular blend comprising about 25-35% by weight of microcrystalline cellulose, about 25-35% by weight of lactose or its hydrate, based on the total amount of the drug composition, about 5% by weight of crospovidone, about 0.5% by weight of silicon dioxide, based on the total amount of the drug composition, and about 0.5% by weight of magnesium stearate, based on the total amount of the drug composition, and an extragranular blend comprising about 0.5% by weight of silicon dioxide, based on the total amount of the drug composition, and (ii) about 0.5% by weight of magnesium stearate, based on the total amount of the drug composition.

[0038] In another embodiment, the present specification provides a compound of formula (I): [ka] The present invention describes a process for the preparation of a solid dispersion comprising an amorphous form of a compound of For example, in the amorphous forms described herein, the process may include (a) mixing a compound of formula (I), a solvent, a polymer, and water to obtain a suspension; (b) optionally stirring and / or mixing the suspension while maintaining a temperature of about 10 to about 25° C.; and (c) dissolving the suspension in a solvent. (d) heating the suspension to dissolve the suspended particles prior to introduction into a spray dryer; (e) spray drying the suspension to obtain a spray-dried dispersion; and (f) drying the spray-dried dispersion, thereby obtaining a solid dispersion. In some embodiments, the method comprises the steps of: [ka] A solid dispersion comprising an amorphous form of the compound of is produced by the process.

[0039] Also provided herein, in another embodiment, is a method of treating a disease selected from the group consisting of gastrointestinal stromal tumor (GIST), KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor, melanoma, acute myeloid leukemia, germ cell tumors, seminoma or dysgerminoma, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, eosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, and non-small cell lung cancer in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of a composition or one or more tablets as described herein.

[0040] Also provided herein, in another embodiment, is a method of treating a disease selected from the group consisting of gastrointestinal stromal tumor (GIST), KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor, lung cancer, glioblastoma, glioma, malignant peripheral nerve sheath sarcoma, and hypereosinophilic syndrome in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a composition or one or more tablets described herein.

[0041] Also provided herein, in another embodiment, is a method of treating a disease selected from the group consisting of KIT-driven germ cell tumors (e.g., testicular germ cell), KIT-driven skin cancer, or KIT-driven renal cell carcinoma, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a composition or one or more tablets described herein.

[0042] Also provided herein, in another embodiment, is a method of treating a disease selected from the group consisting of penile cancer, PDGFRA-driven penile cancer, prostate cancer, PDGFRA-driven prostate cancer, PDGFRA-driven non-melanoma skin cancer, PDGFRA-driven glioma, PDGFRA-driven sarcoma, PDGFRA-driven glioblastoma, or PDGFRA-driven pancreatic cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a composition or one or more tablets described herein.

[0043] Also provided herein, in another embodiment, is a method of treating a disease involving a PDGFRB mutation selected from the group consisting of vaginal cancer, prostate cancer, penile cancer, non-melanoma skin cancer, melanoma, or breast sarcoma in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a composition or one or more tablets described herein.

[0044] In some embodiments, provided herein are methods for treating KIT and PDGFRA mutation-related diseases in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a composition or one or more tablets described herein. In some embodiments, provided herein are methods for treating KIT and PDGFRA mutation-related diseases in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a composition or one or more tablets described herein. In some embodiments, provided herein is a method for treating a disease caused by a KIT mutation or a PDGFRA mutation, including a passenger PDGFRB mutation, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a composition or one or more tablets described herein. In some embodiments, provided herein is a method for treating a disease caused by a gastrointestinal stromal tumor (GIST), an NF-1-deficient gastrointestinal stromal tumor, a succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor, a KIT-driven gastrointestinal stromal tumor, a PDGFRA-driven gastrointestinal stromal tumor, in a patient in need thereof. Methods are provided for treating a disease selected from the group consisting of melanoma (e.g., KIT-driven melanoma or PGDFRA-driven melanoma or PGDFR-driven melanoma), acute myeloid leukemia, seminoma or dysgerminoma germ cell tumors, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, childhood glioma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, eosinophilic syndrome, idiopathic eosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, and non-small cell lung cancer, comprising administering to a patient a therapeutically effective amount of a composition or one or more tablets described herein. In some embodiments, the melanoma is a cutaneous melanoma or a non-cutaneous melanoma. In some embodiments, the melanoma is a cutaneous melanoma. In some embodiments, the cutaneous melanoma is superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, or amelanotic and desmoplastic melanoma. In some embodiments, the melanoma is non-cutaneous (non-skin) melanoma. In some embodiments, the melanoma is cutaneous melanoma or non-cutaneous melanoma is intraocular melanoma or mucosal melanoma. In some embodiments, the disease is caused by the kinase activity of c-KIT and / or PDGFRA, and / or its oncogenic forms. In some embodiments, the disease is selected from the group consisting of KIT-driven germ cell tumors (e.g., testicular germ cell), KIT-driven skin cancer (e.g., KIT-driven squamous cell carcinoma, KIT-driven Merkel cell carcinoma, uveal melanoma, non-melanoma skin cancer), or KIT-driven renal cell carcinoma (e.g., renal cell carcinoma, chromophobe renal cell carcinoma).In some embodiments, the disease is selected from the group consisting of penile cancer, PDGFRA-driven penile cancer, prostate cancer, PDGFRA-driven prostate cancer, PDGFRA-driven non-melanoma skin cancer, PDGFRA-driven glioma, PDGFRA-driven sarcoma, PDGFRA-driven glioblastoma, or PDGFRA-driven pancreatic cancer. In some embodiments, the disease comprising a PDGFRB mutation is selected from the group consisting of vaginal cancer, prostate cancer, penile cancer, non-melanoma skin cancer, melanoma, or breast sarcoma.

[0045] In another embodiment, there is also provided herein a use of a composition or tablet as described herein for the preparation of a medicament for treating a disease selected from the group consisting of gastrointestinal stromal tumor (GIST), KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor, melanoma, acute myeloid leukemia, germ cell tumors of seminoma or dysgerminoma, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, eosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, non-small cell lung cancer. [Brief description of the drawings]

[0046] [Figure 1] FIG. 1 shows the powder X-ray diffraction (PXRD) of a solid dispersion comprising an amorphous form of the compound of formula (I). [Diagram 2] FIG. 2 shows the dissolution profile of an exemplary tablet containing Compound 1 using the dissolution method of Example 8. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0047]

[0048] The features and other details of the present disclosure will now be more particularly described. Certain terms employed in the specification, examples, and appended claims are summarized here. These definitions should be read in light of the remainder of the disclosure as would be understood by one of ordinary skill in the art. Unless otherwise defined, all technical and scientific terms used herein are intended to be understood as meaning the same as in the following examples. Scientific terms have the same meaning as commonly understood by one of ordinary skill in the art.

[0048] definition

[0049] As used herein, the term "excipient" refers to a substance that may be beneficially included in a composition with an active agent. The term "excipient" includes inactive substances as well as functional excipients that may provide beneficial properties to the composition. Exemplary excipients include, but are not limited to, polymers, glidants, sugars, lubricants, salts, buffers, fats, fillers, disintegrants, binders, surfactants, high surface area substrates, flavorings, carriers, matrix materials, and the like.

[0049]

[0050] As used herein, the terms "individual", "patient" or "subject" are used interchangeably herein and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses, or primates, and most preferably humans. The compounds described herein can be administered to mammals, such as humans, but also to other mammals, such as animals requiring veterinary treatment, for example, pet animals (e.g., dogs, cats, etc.), livestock (e.g., cows, sheep, pigs, horses, etc.) and laboratory animals (e.g., rats, mice, guinea pigs, etc.).

[0050]

[0051] As used herein, the terms "pharmacologically acceptable" or "pharmacologically acceptable" include molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to animals or humans, as appropriate. For human administration, preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by FDA Office of Biologics standards.

[0051]

[0052] As used herein, the term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" refers to any solvent, dispersion medium, coating, isotonic and absorption retarding agent, etc., that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The composition may also contain other active compounds that provide complementary, additional, or enhanced therapeutic functions.

[0052]

[0053] As used herein, the term "pharmaceutical composition" refers to a composition containing at least one compound disclosed herein formulated together with one or more pharma- ceutically acceptable carriers.

[0053]

[0054] As used herein, the terms "aniline impurity A," "impurity A," and compound 2 each refer to the compound 3-(5-amino-2-bromo-4-fluorophenyl)-1-ethyl-7-(methylamino)-1,6-naphthyridin-2(1H)-one, which is a compound of formula (II), as described herein. In some embodiments, the aniline-based material may be impurity A.

[0054]

[0055] As used herein, the term "therapeutically effective amount" refers to an amount of a compound of interest that elicits the biological or medical response of a tissue, system, or animal (e.g., a mammal or human) desired by a researcher, veterinarian, physician, or other clinician. The compounds described herein are administered in a therapeutically effective amount to treat a disorder.

[0055]

[0056] As used herein, the term "treating" includes any effect, eg, attenuation, reduction, modulation, or elimination, that results in the improvement of a condition, disease, disorder, or the like.

[0056]

[0057] As used herein, the term "active agent" means a drug, medicament, pharmaceutical, therapeutic agent, such as a compound of Formula (I) as described herein.

[0057]

[0058] As used herein, the term "oral formulation" refers to a composition or vehicle used to administer a compound as disclosed herein (e.g., a compound of formula (I)) to a subject in need thereof by oral administration. Typically, an oral formulation is administered via the mouth, but as used herein, "oral formulation" is intended to encompass any substance that is administered to a subject and absorbed across a membrane, e.g., a mucous membrane, of the digestive tract, including, for example, the mouth, esophagus, stomach, small intestine, large intestine, and colon. In some embodiments, an oral formulation is a pharmaceutical composition. In some embodiments, an oral formulation is a pharmaceutical composition that is administered via the mouth to a subject in need thereof.

[0058]

[0059] As used herein, the term "plasticizer" includes all compounds capable of plasticizing the applied polymer. In general, plasticizers are additives that, when added in either solid or liquid state, can soften plastic polymers, thereby increasing the flexibility of the polymer substrate during the melt extrusion process. Plasticizers generally lower the glass transition temperature and melting point of the polymer. Plasticizers also generally reduce the viscosity of the polymer melt, thereby allowing the processing temperature during hot melt extrusion to be reduced. Examples of compounds that can function as plasticizers include, but are not limited to, glycerin, polyethylene glycols (PEG) (e.g., PEG300, PEG400, PEG1500), phthalates (e.g., diethyl phthalate), polysorbates, sorbitol, citrate esters, triacetin, pluronics (e.g., pluronic P407), Labrasol, and Vitamin E TPGS.

[0059]

[0060] As used herein, the term "stable" refers herein to an amorphous form of the compound of formula (I) that does not convert to any other form and contains less than 5% (wt / wt) total of other forms (e.g., less than 4% w / w, less than 3% w / w, less than 2% w / w) when stored at a temperature up to about 40° C. and a relative humidity of about 25% to about 75% for at least about three months.

[0060]

[0061] As used herein, the term "solid dispersion" refers to any solid composition having at least two components. In certain embodiments, the solid dispersions disclosed herein contain an active ingredient, a compound of formula (I), dispersed between at least one other ingredient (e.g., a polymer).

[0061]

[0062] "Combination therapy" refers to a treatment that includes administration of two or more therapeutic agents, such as a compound of formula I and a MAPKAP pathway inhibitor, to a patient. The two or more therapeutic agents may be delivered simultaneously, e.g., in separate pharmaceutical compositions or in the same pharmaceutical composition, or the two or more therapeutic agents may be delivered at different times. For example, the two or more therapeutic agents may be delivered simultaneously or during overlapping times, and / or one therapeutic agent may be delivered before or after the other therapeutic agent. Combination therapy treatment may include treatment with either single agent preceded or followed by a period of simultaneous treatment with both agents. However, it is intended that during some period of time, an effective amount of the two or more therapeutic agents will be present in the patient's body.

[0062]

[0063] In general, solid forms, such as crystalline or amorphous forms, may be referred to herein as being characterized by graphical data, "as depicted in" or "substantially depicted in" FIG. 1. Such data include, for example, powder X-ray diffractograms and solid-state NMR spectra. As is well known in the art, graphical data can potentially be interpreted in a manner that is not necessarily consistent with reference to numerical values ​​or peak positions alone. The data provide additional technical information to further define each solid form (so-called "fingerprint"), which cannot necessarily be described. In any case, those skilled in the art will be aware that the graphical representation of such data may be subject to small variations in peak relative intensity and peak position due to certain factors, such as, but not limited to, variations in instrument response and variations in sample concentration and purity. Crystals are composed of atoms arranged periodically in 3D space, while in amorphous materials atoms are randomly distributed in 3D space. As a result, the X-ray diffraction pattern of a crystalline material will show narrow peaks of high intensity due to the fact that the X-rays are scattered in only certain directions (due to the periodic arrangement of the atoms). In contrast, the X-ray diffraction pattern of an amorphous material will generally show broad peaks of low intensity (halo pattern) because the X-rays are scattered in many different directions, resulting in large ridges distributed over a wide range (2 theta).

[0063]

[0064] All ranges recited herein include endpoints, including those reciting a range "between" two values. The terms "substantially" and "about" are to be construed as modifying a term or value so as not to make it absolute. This includes, at a minimum, the degree of expected experimental error, technique error, and instrument error for a given technique used to measure the value.

[0064]

[0065] The present invention relates to an amorphous solid dispersion of the amorphous form of the compound of formula (I), optionally in a polymer matrix and the amorphous form of the compound of formula (I). The amorphous nature of the solid dispersion and the amount of crystalline drug can be determined by powder X-ray diffraction (PXRD), scanning electron microscope (SEM) analysis, differential scanning calorimetry (DSC), or any other standard quantitative measurement. For example, a material is X-ray amorphous and no sharp peaks are observed in its PXRD pattern, but rather is described as a halo-like pattern. A sharp peak in the pattern indicates the presence of crystalline material. The amorphous form of the compound of formula (I) can be characterized by an X-ray diffraction pattern substantially as shown in FIG. 1.

[0065]

[0066] The amorphous drug may exist within the solid amorphous dispersion as a pure phase, as a solid solution of drug homogeneously distributed throughout the polymer, or any combination of these states or states in between. The dispersion is preferably substantially homogeneous, such that the amorphous drug is dispersed as homogeneously as possible throughout the polymer. As used herein, "substantially homogeneous" means that a relatively small proportion of the drug is present in relatively pure amorphous domains within the solid dispersion.

[0066] process

[0067] Also provided herein is a process for the preparation of a solid dispersion comprising an amorphous form of a compound of formula (I) described herein, the process comprising: (a) weighing and dispensing a compound of formula (I), a solvent, a polymer, and water; (b) charging and suspending a compound of formula (I); (c) optionally stirring and mixing the final suspension while maintaining a temperature of about 10-25° C.; (d) passing the resulting suspension through an in-line heat exchanger to dissolve the suspended particles prior to introduction into the spray dryer; (e) optionally drying the spray-dried compound of formula (I).

[0067]

[0068] For example, in one embodiment, provided herein is a process for the preparation of a solid dispersion comprising an amorphous form of a compound of formula (I), comprising: [ka] The process includes mixing a compound of formula (I), a solvent (such as hydroxypropylmethylcellulose acetate succinate), a polymer, and water to obtain a suspension, and heating the temperature to about 10 to about 25°C. C, optionally stirring and / or mixing the suspension, heating the suspension to dissolve the suspended particles before introducing it into a spray dryer, spray drying the suspension to obtain a spray-dried dispersion, and drying the spray-dried dispersion, thereby obtaining a solid dispersion. In certain embodiments, the heating comprises passing the suspension through an in-line heat exchanger.

[0068]

[0069] In another embodiment, described herein is a process for the preparation of a solid dispersion comprising an amorphous form of a compound of formula (I), [ka] The process includes: (a) mixing a compound of formula (I), a solvent, a polymer, and water to obtain a suspension; (b) optionally stirring and / or mixing the suspension while maintaining a temperature of about 10°C to about 25°C; (c) heating the suspension to dissolve the suspended particles before introducing it into a spray dryer; (d) spray drying the suspension to obtain a spray-dried dispersion; and (e) drying the spray-dried dispersion, thereby obtaining a solid dispersion. In some embodiments, the heating includes passing the suspension through an in-line heat exchanger. In some embodiments, the solid dispersion comprising an amorphous form of the compound of general formula (I) is: [ka] The process produces:

[0069]

[0070] In some embodiments, the compound of formula (I), the solvent, the polymer, and water are combined. The mixture is stirred and mixed into a suspension. In some embodiments, the solvent, water, and polymer are combined and stirred prior to the addition of the compound of formula (I). In some embodiments, the solvent and water are combined and stirred prior to the addition of the polymer and compound of formula (I). In some embodiments, the solvent and water are combined and stirred, followed by the addition of the polymer, followed by the compound of formula (I).

[0070]

[0071] In some embodiments, the solvent:water ratio may be about 95:5, followed by the addition and dissolution of the polymer. In some embodiments, the solvent:water ratio may be about 90:10, followed by the addition and dissolution of the polymer. In some embodiments, the solvent:water ratio may be about 85:15, followed by the addition and dissolution of the polymer. In some embodiments, the solvent:water ratio may be about 80:20, followed by the addition and dissolution of the polymer. In some embodiments, the solvent:water ratio may be about 75:25, followed by the addition and dissolution of the polymer. In some embodiments, the solvent:water ratio may be about 70:30, followed by the addition and dissolution of the polymer. In some embodiments, the solvent:water ratio may be about 65:35, followed by the addition and dissolution of the polymer. In some embodiments, the solvent:water ratio may be about 60:40, followed by the addition and dissolution of the polymer. In some embodiments, the solvent:water ratio may be about 55:45, followed by the addition and dissolution of the polymer. In some embodiments, the solvent:water ratio may be about 50:50, followed by addition and dissolution of the polymer.

[0071]

[0072] In some embodiments, the solvent is an organic compound in which the active agent and the polymer are mutually soluble. In some embodiments, the solvent is an alcohol, a ketone, an ether, an ester, a halogenated alkane, an amide, a sulfone, an acid, or a nitro compound. In some embodiments, the solvent is methanol, ethanol, n-propanol, isopropanol, or butanol. In some embodiments, the solvent is acetone, methyl ethyl ketone (MEK), or methyl isobutyl ketone (MIBK). In some embodiments, the solvent is methyl acetate, ethyl acetate, or propyl acetate. In some embodiments, the solvent is diethyl ether, tetrahydrofuran (THF), 2-methyl THF, 2,5-dimethyl THF, or 2,2,5,5-tetramethyl THF. In some embodiments, the solvent is acetonitrile, methylene chloride, toluene, 1,1,1-trichloroethane, dimethylacetamide (DMA), nitromethane, acetic acid, or dimethyl sulfoxide (DMSO). Mixtures of solvents and water are suitable so long as the polymer and the compound of formula (I) are sufficiently soluble to make a spray drying process practical. In some embodiments, the water:solvent mixture is water:acetone. In some embodiments, the water:solvent mixture is water:THF. In some embodiments, the water:solvent mixture is water:methanol. In some embodiments, the water:solvent mixture is water:ethanol. In some embodiments, the water:solvent mixture is water:methyl ethyl ketone. In some embodiments, the water:solvent mixture is water:ethyl acetate. In some embodiments, the water:solvent mixture is water:methylene chloride. In some embodiments, mixtures of solvents are suitable so long as the polymer and the compound of formula (I) are sufficiently soluble to make a spray drying process practical. In some embodiments, the solvent:solvent mixture is methanol:ethyl acetate. In some embodiments, the solvent:solvent mixture is ethanol:ethyl acetate. In some embodiments, the solvent:solvent mixture is methanol:dichloromethane. In some embodiments, the solvent:solvent mixture is ethanol:dichloromethane.

[0072]

[0073] In some embodiments, the solvent is an organic compound in which the active agent is suspended.In some embodiments, the compound of formula (I) is suspended in a mixture of purified water and THF before adding polymer.In some embodiments, compound 1 is suspended in a mixture of purified water and THF before adding HPMCAS-HG.

[0073]

[0074] In some embodiments, the temperature range of stirring and mixing the final suspension is about 0-25°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 5-25°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 10-25°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 15-25°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 15-24°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 15-23°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 15-22°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 15-21°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 15-20°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 17-25°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 17-24°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 17-23°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 17-22°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 17-21°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 17-20°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 18-25°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 18-24°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 18-23°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 18-22°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 18-21°C. In some embodiments, the temperature range of stirring and mixing the final suspension is about 18-20°C.

[0074]

[0075] In some embodiments, the suspension flow rate through the in-line heat exchanger operating range may be about 5-100 kg / hr. In some embodiments, the suspension flow rate through the in-line heat exchanger operating range may be about 5-30 kg / hr. In some embodiments, the suspension flow rate through the in-line heat exchanger operating range may be about 5-25 kg / hr. In some embodiments, the suspension flow rate through the in-line heat exchanger operating range may be about 5-20 kg / hr. In some embodiments, the suspension flow rate through the in-line heat exchanger operating range may be about 5-15 kg / hr. In some embodiments, the suspension flow rate through the in-line heat exchanger operating range may be about 5-10 kg / hr. In some embodiments, the suspension flow rate through the in-line heat exchanger operating range may be about 30-50 kg / hr. In some embodiments, the suspension flow rate is about 35-45 kg / hr. In some embodiments, the suspension flow rate is about 35-40 kg / hr. In some embodiments, the suspension flow rate is about 40-45 kg / hr. In some embodiments, the suspension flow rate is about 42-48 kg / hr. In some embodiments, the suspension flow rate is about 45-50 kg / hr. In some embodiments, the suspension flow rate through the in-line heat exchanger operating range may be about 50-100 kg / hr. In some embodiments, the suspension flow rate is about 50-90 kg / hr. In some embodiments, the suspension flow rate is about 50-80 kg / hr. In some embodiments, the suspension flow rate is about 50-70 kg / hr. In some embodiments, the suspension flow rate is about 50-60 kg / hr.

[0075]

[0076] In some embodiments, the solution temperature near or at the nozzle of the spray dryer may be about 110-130°C, preferably about 115-125°C, most preferably about 116°C, about 117°C, about 118°C, about 119°C, about 120°C, about 121°C, about 122°C, about 123°C, about 124°C, about 125°C. In some embodiments, the solution temperature near or at the nozzle of the spray dryer may be about 15-25°C. In some embodiments, the solution temperature near or at the nozzle of the spray dryer may be about 20-25°C. In some embodiments, the solution temperature near or at the nozzle of the spray dryer may be about 10-100°C. In some embodiments, the solution temperature near or at the nozzle of the spray dryer may be about 10-200°C. The solution temperature near or at the nozzle of the spray dryer may be about 20-90°C. In some embodiments, the solution temperature near or at the nozzle of the spray dryer may be about 20-80°C. In some embodiments, the solution temperature near or at the nozzle of the spray dryer may be about 20-70°C. In some embodiments, the solution temperature near or at the nozzle of the spray dryer may be about 20-60°C. In some embodiments, the solution temperature near or at the nozzle of the spray dryer may be about 20-50°C. In some embodiments, the solution temperature near or at the nozzle of the spray dryer may be about 20-40°C. In some embodiments, the solution temperature near or at the nozzle of the spray dryer may be about 20-30°C.

[0076]

[0077] In some embodiments, the spray dryer nozzle sheath gas pressure may be about 50-100 psig. In some embodiments, the spray dryer bulk drying gas flow rate may be about 400-500 kg / hr. In some embodiments, the spray dryer chamber outlet temperature may be about 45-75° C. In some embodiments, the spray dryer condenser temperature may be about −5° C. to about −20° C.

[0077]

[0078] After spray drying is completed, the spray dried intermediate is optionally subjected to a secondary spray drying in an agitated vacuum dryer. In some embodiments, the drying temperature may be about 30-60°C, preferably about 35-55°C, and most preferably about 40-50°C. In some embodiments, the drying duration should not be less than about 3 hours, preferably less than about 6 hours, less than about 7 hours, less than about 8 hours, or less than about 9 hours. In some embodiments, the chamber pressure may be about 30-60 mbar, preferably about 35-55 mbar, and most preferably about 40-50 mbar.

[0078]

[0079] In some embodiments, the polymer may be ionic. In some embodiments, the polymer may be non-ionic.In some embodiments, the pharma- ceutically acceptable polymer is selected from the group consisting of polyvinylpyrrolidone, polyethylene oxide, polyethylene glycol, poly(vinylpyrrolidone-co-vinyl acetate), polyoxyethylene-polyoxypropylene block copolymers, graft copolymers (composed of polyethylene glycol, polyvinylcaprolactam and polyvinyl acetate), polymethacrylates, polyoxyethylene alkyl ethers, polyoxyethylene castor oil, polycaprolactam, polylactic acid, polyglycolic acid, poly(lactic-glycolic) acid, lipids, cellulose, pullulan, dextran, maltodextrin, hyaluronic acid, polysialic acid, chondroitin sulfate, heparin, fucoidan, pentosan polysulfate, spirulan, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose propionate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, methylcellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, carboxymethylcellulose acetate, cellulose acetate terephthalate, cellulose acetate isophthalate, cellulose acetate tere ... ethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate phthalate, hydroxypropyl methylcellulose propionate phthalate, hydroxypropyl methylcellulose acetate trimellitate, hydroxypropyl methylcellulose propionate trimellitate, cellulose acetate succinate, methylcellulose acetate succinate, dextran, dextran acetate salt, dextran tropionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran propionic acid succinate, dextran acetate propionic acid succinate, poly(methacrylic acid-co-methyl methacrylate) 1:1, poly(methacrylic acid-co-methyl methacrylate) 1:2, poly(methacrylic acid-co-ethyl acrylate) 1:1, hydroxyethyl cellulose, methylcellulose and hydroxypropyl cellulose, polymethacrylic acid-ethyl acrylate, polymethacrylic acid-methyl methacrylate, polymethyl methacrylate-ethyl acrylate, polytrimethylammonioethyl methacrylate, polymethylmethacrylate-ethyl acrylate. In one embodiment, the medicament is a pharma- ceutically acceptable polymer selected from the group consisting of poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate), and mixtures thereof. In some embodiments, the pharma- ceutically acceptable polymer is polyvinylpyrrolidone, polyethylene oxide, polyethylene glycol, poly(vinylpyrrolidone-co-vinyl acetate), polyoxyethylene-polyoxypropylene block copolymers, graft copolymers (composed of polyethylene glycol, polyvinylcaprolactam, and polyvinyl acetate), polymethacrylates, polyoxyethylene alkyl ethers, polyoxyethylene castor oil, polycaprolactam, polylactic acid, polyglycolic acid, poly(lactic-glycolic) acid, lipids, cellulose, pullulan, dextran, maltodextrin, hyaluronic acid, polysialic acid, chondroitin sulfate, heparin, fucoidan, pentosan polysulfate, spirulan, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose propionate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, methylcellulose acetate phthalate. , hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, carboxymethyl ethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate phthalate, hydroxypropyl methylcellulose propionate phthalate, hydroxypropyl methylcellulose acetate trimellitate, hydroxypropyl methylcellulose propionate, cellulose acetate succinate, methyl cellulose acetate succinate, dextran, dextran acetate, dextran tropionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran tropionate succinate, dextran acetate propionate succinate, poly(methacrylic acid-co-methyl methacrylate) 1:1, poly(methacrylic acid-co-methyl methacrylate) 1:2, poly(methacrylic acid-co-ethyl acrylate) 1:1, and mixtures thereof.In some embodiments, the polymer is hydroxypropyl methylcellulose, hydroxypropyl cellulose, carboxymethylethylcellulose, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, polyvinyl alcohol having at least a portion of their repeat units in hydrolyzed form, polyvinylpyrrolidone, poloxamer, or blends thereof. In some embodiments, the pharma- ceutically acceptable polymer is hydroxypropyl methylcellulose acetate succinate.

[0079]

[0080] Characterization of crystalline and amorphous forms In one general embodiment, the compound of formula (I) free base may be used as the starting material or may be prepared by the methods further described in US 8,940,756 and US 8,461,179, which are incorporated herein by reference.

[0080]

[0081] In one general embodiment, an amorphous form of the compound of formula (I) is provided. [ka]

[0081]

[0082] In another general embodiment, an amorphous form of the compound of Formula (I) is provided having a purity by HPLC of greater than about 95% and less than about 0.5% residual solvent.

[0082]

[0083] In general, the amorphous form of the compound of formula (I) is substantially free of residual solvent. The term "substantially free" refers to residual solvent within the acceptable ICH limits suitable for pharmaceutical preparations. In some embodiments, the amorphous form of the compound of formula (I) contains less than 1% residual solvent. In some embodiments, the amorphous form of the compound of formula (I) contains less than 0.9% residual solvent. In some embodiments, the amorphous form of the compound of formula (I) contains less than 0.8% residual solvent. In some embodiments, the amorphous form of the compound of formula (I) contains less than 0.7% residual solvent. In some embodiments, the amorphous form of the compound of formula (I) contains less than 0.6% residual solvent. In some embodiments, the amorphous form of the compound of formula (I) contains less than 0.5% residual solvent. In some embodiments, the amorphous form of the compound of formula (I) contains less than 0.4% residual solvent. In some embodiments, the amorphous form of the compound of formula (I) contains less than 0.3% residual solvent. In some embodiments, the amorphous form of the compound of formula (I) contains less than 0.2% residual solvent. In some embodiments, the amorphous form of the compound of formula (I) contains less than 0.1% residual solvent.

[0083]

[0084] In another general aspect, provided herein is an amorphous form of a compound of Formula (I) having a purity by HPLC of greater than about 95%. In some embodiments, the purity by HPLC is greater than about 96%. In some embodiments, the purity by HPLC is greater than about 97%. In some embodiments, the purity by HPLC is greater than about 98%. In some embodiments, the purity by HPLC is greater than about 99%. In some embodiments, the purity by HPLC is greater than about 99.5%. In some embodiments, the purity by HPLC is greater than about 99.8%. In some embodiments, the purity by HPLC is greater than about 99.9%. In some embodiments, the purity by HPLC is greater than about 90%. In some embodiments, the purity by HPLC is greater than about 92%. In some embodiments, the purity by HPLC is greater than about 94%.

[0084]

[0085] In another aspect, it is provided herein that the amorphous form of the compound of formula (I) is substantially free of any other crystalline form. In some embodiments, the amorphous form of the compound of formula (I) contains less than about 5% of other crystalline forms. In some embodiments, the amorphous form of the compound of formula (I) contains no more than about 5% (w / w) of any crystalline form or does not contain any detectable amount of any crystalline form. The amorphous form provided herein does not essentially convert to any crystalline form of the compound of formula (I) under various conditions, i.e., contains no more than about 10% (w / w), about 5% (w / w), about 4% (w / w), about 3% (w / w), about 2% (w / w), about 1% (w / w), about 0.5% (w / w) of any crystalline form of the compound of formula (I).

[0085]

[0086] As used herein, "substantially free of any other form" means that the amorphous form of the compound of formula (I) in the solid state contains about 20% or less, about 10% or less, about 5% or less, about 2% or less, or about 1% or less of any other form of the compound of interest, as measured, for example, by PXRD, or contains less than about 20%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% of any other form of the compound of interest, as measured, for example, by PXRD. Thus, the amorphous form of the compound of formula (I) in the solid state of interest described herein as being substantially free of any other solid state is understood to contain more than 80% (w / w), more than 90% (w / w), more than 95% (w / w), more than 98% (w / w), or more than 99% (w / w) of the compound of formula (I). Thus, in some embodiments, the described solid forms of an amorphous form of the compound of formula (I) may contain 1% to 20% (w / w), 5% to 20% (w / w), or 5% to 10% (w / w) of one or more other solid forms of the compound of formula (I). .

[0086]

[0087] As used herein, "free from detectable amounts of any crystalline form" means that the amorphous form of the compound of formula (I) in the solid state contains an amount of crystalline form that is not more than detectable by a detection and / or measurement instrument, for example, by PXRD. This amount can contain, for example, less than about 4% w / w, less than about 3% w / w, less than about 2% w / w, or less than about 1% w / w of any other form of the subject compound, as measured by PXRD. This amount is preferably less than 4% w / w, less than 3% w / w, less than 2% w / w, or less than 1% w / w.

[0087]

[0088] The content of the solid form is typically measured by any suitable method recognized by one of skill in the art, such as PXRD, solid state NMR, IR, Raman, or DSC.

[0088]

[0089] Exemplary analytical methods are as follows: Powder X-ray diffraction may be performed using a Rigaku D / MAX 2200 VPC diffractometer, or a PANALYTICAL ExpertPro DY2408, or indeed any other suitable machine, and powder X-ray diffraction patterns were measured at room temperature using a Cu Kα filled tube (40 kV, 40 mA) as the X-ray source with a wide-angle goniometer, 1° scattering slit, 1° divergence slit, and a graphite secondary monochromator, and a scintillation counter. Data collection was performed in 2-theta continuous scan mode, with a scan speed of 3° / min, a scan step of 0.02°, and a range of 2°-40°.

[0089]

[0090] In one aspect, provided herein is an amorphous form of the compound of formula (I), which contains no more than 5% (w / w) of any crystalline form or no detectable amount of any crystalline form when stored at temperatures up to about 40° C. and at a relative humidity of about 25% to about 75% for about 3 months. The present invention includes amorphous forms of the compound of formula (I) in stable form. In some embodiments, the amorphous forms are essentially not converted to any crystalline form of the compound of formula (I) under various conditions. That is, they include no more than 10% (w / w), 5% (w / w), 4% (w / w), 3% (w / w), 2% (w / w), 1% (w / w), 0.5% (w / w) ("NMT") of any crystalline form. In some embodiments, the amorphous form of the compound of formula (I) contains no more than 10% (w / w) of any crystalline form, and preferably no detectable amount of any crystalline form, when stored at 25° C. and under the following conditions: At 0% relative humidity for 3 days, preferably 7 days, or at 20% relative humidity for 3 days, preferably 7 days, or at 40% relative humidity for 3 days, preferably 7 days, or at 60% relative humidity for 3 days, preferably 7 days, or at 80% relative humidity for 3 days, preferably 7 days, or at 100% relative humidity for 3 days, preferably 7 days. In some embodiments, the amorphous form of the compound of formula (I) described herein does not convert to a crystalline compound of formula (I) under conditions of 0-100% relative humidity at 25° C.-40° C. for at least 0-360 days. In some embodiments, the amorphous form of the compound of formula (I) contains no more than 10% (w / w) of any crystalline form, and preferably does not contain a detectable amount of any crystalline form, when stored at 25° C. and 60% relative humidity (RH) for 3 days, preferably 7 days. In some embodiments, the amorphous form of the compound of formula (I) contains no more than 10% (w / w) of any crystalline form, and preferably no detectable amount of any crystalline form, when stored at 25° C. and 80% relative humidity (RH) for 3 days, preferably 7 days. In some embodiments, the amorphous form of the compound of formula (I) contains no more than 5% of any crystalline form, and preferably no detectable amount of any crystalline form, when exposed to 0-100% relative humidity for 7 days at 25° C. In some embodiments, the amorphous form of the compound of formula (I) contains no more than 5% of any crystalline form, and preferably no detectable amount of any crystalline form, when exposed to 0-100% relative humidity for 30 days at 25° C. In some embodiments, the amorphous form of the compound of formula (I) contains no more than 5% of any crystalline form, and preferably no detectable amount of any crystalline form, when exposed to 0-100% relative humidity for 60 days at 25° C. In some embodiments, the amorphous form of the compound of formula (I) comprises no more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 3 months. In some embodiments, the amorphous form of the compound of formula (I) comprises no more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 4 months. In some embodiments, the amorphous form of the compound of formula (I) comprises no more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 5 months. In some embodiments, the amorphous form of the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 6 months. In some embodiments, the amorphous form of the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 7 months. In some embodiments, the amorphous form of the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 8 months. In some embodiments, the amorphous form of the compound of formula (I) comprises not more than about 5% (w / w), or some detectable amount of any crystalline form of the compound of formula (I), when exposed to 0-75% relative humidity for 9 months at 25° C.-40° C. In some embodiments, the amorphous form of the compound of formula (I) comprises not more than about 5% (w / w), or some detectable amount of any crystalline form of the compound of formula (I), when exposed to 0-75% relative humidity for 10 months at 25° C.-40° C.In some embodiments, the amorphous form of the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 11 months. In some embodiments, the amorphous form of the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 12 months. In some embodiments, the amorphous form of the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 13 months. In some embodiments, the amorphous form of the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form of the compound of formula (I) when exposed to 0-100% relative humidity at 25° C.-40° C. for 14 months. In some embodiments, the amorphous form of the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form of the compound of formula (I) when exposed to 0-100% relative humidity at 25° C.-40° C. for 15 months. In some embodiments, the amorphous form of the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form of the compound of formula (I) when exposed to 0-100% relative humidity at 25° C.-40° C. for 16 months. In some embodiments, the amorphous form of the compound of formula (I) comprises not more than about 5% (w / w), or some detectable amount of any crystalline form of the compound of formula (I) when exposed to 0-100% relative humidity for 17 months at 25° C.-40° C. In some embodiments, the amorphous form of the compound of formula (I) comprises not more than about 5% (w / w), or some detectable amount of any crystalline form of the compound of formula (I) when exposed to 0-100% relative humidity for 18 months at 25° C.-40° C.In some embodiments, the amorphous form of the compound of formula (I) has no more than about 5% (w / w) of any crystalline form, or any detectable amount of any crystalline form of the formula, when exposed to 0-100% relative humidity at 25° C.-40° C. for 2 years. (I). In some embodiments, the relative humidity is about 10%. In some embodiments, the relative humidity is about 20%. In some embodiments, the relative humidity is about 30%. In some embodiments, the relative humidity is about 40%. In some embodiments, the relative humidity is about 50%. In some embodiments, the relative humidity is about 60%. In some embodiments, the relative humidity is about 70%. In some embodiments, the relative humidity is about 80%. In some embodiments, the relative humidity is about 90%. In some embodiments, the temperature is 25° C. In some embodiments, the relative humidity is about 90%. In some embodiments, the temperature is 30° C. In some embodiments, the relative humidity is about 90%. In some embodiments, the temperature is 35° C. In some embodiments, the relative humidity is about 90%. In some embodiments, the temperature is 40° C.

[0090]

[0091] In some embodiments, the amorphous form of the compound of formula (I) is in a very pure and stable form. High purity and amorphous form typically has an HPLC purity of at least 95% (w / w), preferably at least 96% (w / w), preferably at least 97% (w / w), preferably at least 98% (w / w), preferably at least 99% (w / w), and does not convert to the crystalline form described herein.Therefore, as disclosed herein, the amorphous form of the compound of formula (I) can be not only of high chemical purity, but also of high polymorphic purity. The highly pure, amorphous form of the compound of formula (I) contains no more than 10% (w / w), no more than 5% (w / w), no more than 4% (w / w), no more than 3% (w / w), no more than 2% (w / w), no more than 1% (w / w) of any crystalline form when stored under the conditions exemplified in Tables 2(a)-(c), including the amorphous form of the compound of formula (I) prepared according to Example 1 hereinafter. In particular, the amorphous form of the compound of formula (I) is surprisingly highly stable and does not exhibit polymorphic conversion to a crystalline form under harsh conditions of high relative humidity and high temperature.

[0091]

[0092] In one aspect, provided herein is a solid dispersion comprising an amorphous form of the compound of formula (I), which contains no more than 5% (w / w) of any crystalline form or no detectable amount of any crystalline form when stored at a temperature up to about 40° C. and a relative humidity of about 25% to about 75% for about 3 months. The present invention includes a solid dispersion comprising an amorphous form of the compound of formula (I) in a stable form. In some embodiments, the solid dispersion comprising an amorphous form is essentially not converted to any crystalline form of the compound of formula (I) under various conditions. That is, it contains no more than 10% (w / w), 5% (w / w), 4% (w / w), 3% (w / w), 2% (w / w), 1% (w / w), 0.5% (w / w) ("NMT") of any crystalline form. In some embodiments, the solid dispersions comprising the amorphous form of the compound of formula (I) contain no more than 10% (w / w) of any crystalline form, and preferably no detectable amount of any crystalline form, when stored at 25° C. and under the following conditions: 0% relative humidity for 3 days, preferably 7 days, or 20% relative humidity for 3 days, preferably 7 days, or 40% relative humidity for 3 days, preferably 7 days, or 60% relative humidity for 3 days, preferably 7 days, or 80% relative humidity for 3 days, preferably 7 days, or 100% relative humidity for 3 days, preferably 7 days. In some embodiments, the solid dispersions comprising the amorphous form of the compound of formula (I) described herein do not convert to the crystalline compound of formula (I) under conditions of 0-100% relative humidity at 25° C.-40° C. for at least 0-360 days. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) comprises no more than 10% (w / w), and preferably no detectable amount of any crystalline form, when stored at 25° C. and 60% relative humidity (RH) for 3 days, preferably 7 days. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) comprises no more than 10% (w / w), and preferably no detectable amount of any crystalline form, when stored at 25° C. and 80% relative humidity (RH) for 3 days, preferably 7 days. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) comprises no more than 5% and preferably no detectable amount of any crystalline form, when exposed to 0-100% relative humidity at 25° C. for 7 days.In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) comprises no more than 5%, preferably no detectable amount, of any crystalline form when exposed to 0-100% relative humidity at 25° C. for 30 days. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) comprises no more than 5%, preferably no detectable amount, of any crystalline form when exposed to 0-100% relative humidity at 25° C. for 60 days. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) comprises no more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form, of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 3 months. In some embodiments, a solid dispersion comprising an amorphous form of the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form, of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 4 months. In some embodiments, a solid dispersion comprising an amorphous form of the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form, of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 5 months. In some embodiments, a solid dispersion comprising an amorphous form of the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form, of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 6 months. In some embodiments, a solid dispersion comprising a compound of formula (I) comprises not more than about 5% (w / w), or some detectable amount of any crystalline form of the compound of formula (I) when exposed to 0-75% relative humidity for 7 months at 25° C.-40° C. In some embodiments, a solid dispersion comprising a compound of formula (I) comprises not more than about 5% (w / w), or some detectable amount of any crystalline form of the compound of formula (I) when exposed to 0-75% relative humidity for 8 months at 25° C.-40° C.In some embodiments, the solid dispersion comprising the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form, of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 9 months. In some embodiments, the solid dispersion comprising the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form, of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 10 months. In some embodiments, the solid dispersion comprising the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form, of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 11 months. In some embodiments, the solid dispersion comprising the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form, of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 12 months. In some embodiments, the solid dispersion comprising the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form, of the compound of formula (I) when exposed to 0-75% relative humidity at 25° C.-40° C. for 13 months. In some embodiments, the solid dispersion comprising the compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form, of the compound of formula (I) when exposed to 0-100% relative humidity at 25° C.-40° C. for 14 months. In some embodiments, a solid dispersion comprising a compound of formula (I) comprises not more than about 5% (w / w), or some detectable amount of any crystalline form, of the compound of formula (I) when exposed to 0-100% relative humidity for 15 months at 25° C.-40° C. In some embodiments, a solid dispersion comprising a compound of formula (I) comprises not more than about 5% (w / w), or some detectable amount of any crystalline form, of the compound of formula (I) when exposed to 0-100% relative humidity for 16 months at 25° C.-40° C.In some embodiments, the solid dispersion comprising the compound of formula (I) contains no more than about 5% (w / w) of any crystalline form, or any detectable amount of the compound of formula (I) when exposed to 0-100% relative humidity at 25° C.-40° C. for 17 months. A solid dispersion comprising a compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form, of the compound of formula (I) when exposed to 0-100% relative humidity at 25° C.-40° C. for 18 months. In some embodiments, a solid dispersion comprising a compound of formula (I) comprises not more than about 5% (w / w) of any crystalline form, or some detectable amount of any crystalline form, of the compound of formula (I) when exposed to 0-100% relative humidity at 25° C.-40° C. for 2 years. In some embodiments, the relative humidity is about 10%. In some embodiments, the relative humidity is about 20%. In some embodiments, the relative humidity is about 30%. In some embodiments, the relative humidity is about 40%. In some embodiments, the relative humidity is about 50%. In some embodiments, the relative humidity is about 60%. In some embodiments, the relative humidity is about 70%. In some embodiments, the relative humidity is about 80%. In some embodiments, the relative humidity is about 90%. In some embodiments, the temperature is 25° C. In some embodiments, the relative humidity is about 90%. In some embodiments, the temperature is 30° C. In some embodiments, the relative humidity is about 90%. In some embodiments, the temperature is 35° C. In some embodiments, the relative humidity is about 90%. In some embodiments, the temperature is 40° C.

[0092]

[0093] In some embodiments, the solid dispersions described herein contain less than about 0.05% (w / w) (e.g., about 0.01% to about 1% w / w, or about 0.01% to about 0.08% w / w) of 3-(5-amino-2-bromo-4-fluorophenyl)-1-ethyl-7-(methylamino)-1,6-naphthyridin-2(1H)-one, aniline, or a combination thereof, as detected by HPLC.

[0093]

[0094] In some embodiments, the amorphous form of the compound of formula (I) is in a very pure and stable form. High purity and amorphous form typically has an HPLC purity of at least 95% (w / w), preferably at least 96% (w / w), preferably at least 97% (w / w), preferably at least 98% (w / w), preferably at least 99% (w / w), and does not convert to the crystalline form described herein.Therefore, as disclosed herein, the solid dispersion comprising the compound of formula (I) can be not only of high chemical purity, but also of high polymorphic purity. The highly pure, amorphous form of the compound of formula (I) contains not more than 10% (w / w), not more than 5% (w / w), not more than 4% (w / w), not more than 3% (w / w), not more than 2% (w / w), not more than 1% (w / w) of any crystalline form when stored under the conditions exemplified in Tables 2(a)-(c), including solid dispersions comprising the compound of formula (I) prepared according to Example 1 hereinafter. In particular, solid dispersions comprising the amorphous form of the compound of formula (I) are surprisingly highly stable and do not exhibit polymorphic conversion to the crystalline form under harsh conditions of high relative humidity and high temperature.

[0094]

[0095] In one embodiment, the amorphous form of the compound of formula (I) is characterized by an X-ray diffraction pattern substantially as shown in Figure 1. Described herein are amorphous forms of the compound of formula (I). The amorphous form may be characterized by an amorphous "halo" PXRD pattern, an X-ray powder diffraction pattern substantially as shown in Figure 1, and combinations of this data. The amorphous form of the compound of formula (I) may be prepared by the process of dissolving the compound of formula (I), spray drying the solution of the compound, and drying the spray dried compound.

[0095]

[0096] In one aspect, the solid dispersion comprising the amorphous form of the compound of formula (I) has unexpectedly high solubility (Table 3). In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) has about 10 times higher solubility than the crystalline compound. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) has about 20 times higher solubility than the crystalline compound. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) has about 30 times higher solubility than the crystalline compound. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) has about 40 times higher solubility than the crystalline compound. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) has a solubility of about 50 times higher than the crystalline compound. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) has a solubility of about 60 times higher than the crystalline compound. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) has a solubility of about 70 times higher than the crystalline compound. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) has a solubility of about 80 times higher than the crystalline compound. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) has a solubility of about 90 times higher than the crystalline compound. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) has a solubility of about 100 times higher than the crystalline compound. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) has a solubility of about 110 times higher than the crystalline compound. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) has a solubility of about 120 times higher than the crystalline compound. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) has a solubility of about one order of magnitude higher than the crystalline compound. In some embodiments, the solid dispersion comprising the amorphous form of the compound of formula (I) has a solubility of about two orders of magnitude higher than the crystalline compound.

[0096]

[0097] In one aspect, the solid dispersions comprising the amorphous form of the compound of formula (I) have an unexpectedly enhanced pharmacokinetic profile (Table 4). In some embodiments, the solid dispersions comprising the amorphous form of the compound of formula (I) have a maximum concentration (C) of about 5-fold higher than that of the crystalline compound. max In some embodiments, the solid dispersion comprising an amorphous form of the compound of formula (I) has a maximum concentration (C) of about 7-fold that of the crystalline compound. max In some embodiments, the solid dispersion comprising an amorphous form of the compound of formula (I) has a maximum concentration (C) of about 10 times that of the crystalline compound. max In some embodiments, the solid dispersion comprising an amorphous form of the compound of formula (I) has a maximum concentration (C) of about 12 times that of the crystalline compound. max In some embodiments, the solid dispersion comprising an amorphous form of the compound of formula (I) has a maximum concentration (C) of about 15 times that of the crystalline compound. max In some embodiments, the solid dispersion comprising an amorphous form of the compound of formula (I) has a maximum concentration (C) of about 20 times that of the crystalline compound. max In some embodiments, the solid dispersion comprising an amorphous form of the compound of formula (I) has a total drug exposure (AUC (0-∞) In some embodiments, the solid dispersion comprising an amorphous form of the compound of formula (I) has a total drug exposure (AUC (0-∞) In some embodiments, the solid dispersion comprising an amorphous form of the compound of formula (I) has a total drug exposure (AUC (0-∞) In some embodiments, the solid dispersion comprising an amorphous form of the compound of formula (I) has a total drug exposure (AUC (0-∞) In some embodiments, the solid dispersion comprising an amorphous form of the compound of formula (I) has a total drug exposure (AUC (0-∞) In some embodiments, the solid dispersion comprising an amorphous form of the compound of formula (I) has a total drug exposure (AUC (0-∞) ).

[0097] spray dried dispersion

[0098] As described herein, the dispersion of an active agent and a pharma- ceutically acceptable polymer is made by a spray drying process. As used herein, the term "spray dried dispersion" or "spray dried powder dispersion" refers to the product of a spray drying process, the product comprising a dispersion of at least one active agent and at least one excipient, such as a polymer. In some embodiments, the polymer is selected from the group consisting of polyvinylpyrrolidone, polyethylene oxide, polyethylene glycol, poly(vinylpyrrolidone-co-vinyl acetate), polyoxyethylene-polyoxypropylene block copolymers, graft copolymers (composed of polyethylene glycol, polyvinylcaprolactam and polyvinyl acetate), polymethacrylates, polyoxyethylene alkyl ethers, polyoxyethylene castor oil, polycaprolactam, polylactic acid, polyglycolic acid, poly(lactic-glycolic) acid, lipids, sucrose, glycerol ... cellulose, pullulan, dextran, maltodextrin, hyaluronic acid, polysialic acid, chondroitin sulfate, heparin, fucoidan, polysulfate pentosan, spirulan, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose propionate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, methylcellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, carboxymethylethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate phthalate, hydroxypropyl methylcellulose propionate phthalate, hydroxypropyl methylcellulose acetate trimellitate, hydroxypropyl methylcellulose propionate trimellitate, cellulose acetate succinate, methylcellulose acetate succinate, The pharma- ceutically acceptable polymer is selected from the group consisting of dextran, dextran acetate, dextran tropionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran tropionate succinate, dextran acetate propionate succinate, poly(methacrylic acid-co-methyl methacrylate) 1:1, poly(methacrylic acid-co-methyl methacrylate) 1:2, poly(methacrylic acid-co-ethyl acrylate) 1:1, hydroxyethyl cellulose, methyl cellulose and hydroxypropyl cellulose, polymethacrylic acid-ethyl acrylate, polymethacrylic acid-methyl methacrylate, polymethyl methacrylate-ethyl acrylate, polytrimethylammonioethyl methacrylate, methyl methacrylate-ethyl acrylate and poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate), and mixtures thereof.

[0098]

[0099] In the spray drying process, the active agent and one or more polymers are dissolved in a common solvent. Here, "common" means that the solvent, which can be a mixture of compounds, dissolves both the active agent and the polymer(s). After both the active agent and the polymer are dissolved, the solvent is rapidly removed by evaporation in the spray drying apparatus, resulting in the formation of a substantially uniform solid dispersion. In such a dispersion, the active agent is dispersed as uniformly as possible throughout the polymer, and can be considered as a solid solution of the active agent dispersed in the polymer(s).

[0099]

[0100] The solvent is removed by the spray drying process. The term "spray drying" is conventionally used and broadly refers to a process that involves breaking up a liquid mixture into small droplets (atomization) and rapidly removing the solvent from the mixture in a spray drying apparatus where there is a strong driving force for evaporation of the solvent from the droplets. The spray drying process and spray drying equipment are generally described in Perry's Chemical Engineers' Handbook, pages 20-54 to 20-57 (Sixth Edition 1984). For more information on the spray drying process and equipment, see Marshall, "Atomization and Spray-Drying," 50 Chem. Eng. Prog. Monogr. Series 2 (1954) , and Masters, Spray Drying Handbook (Fourth Edition 1985). Additionally, additional process and spray drying techniques and equipment are generally described in US8.343.550 and US7,780,988, the contents of which are incorporated herein by reference in their entirety for all purposes. A strong driving force for solvent evaporation is generally provided by maintaining the partial pressure of the solvent in the spray drying apparatus well below the vapor pressure of the solvent at the temperature of the drying droplets. This is accomplished by (1) maintaining the pressure in the spray drying apparatus at a partial vacuum (e.g., 0.01 to 0.50 atm), or (2) mixing the droplets with a warm drying gas, or (3) both (1) and (2). In addition, a portion of the heat required for solvent evaporation may be provided by heating the spray solution.

[0100]

[0101] The drying gas can be virtually any gas, but inert gases such as nitrogen, nitrogen-enriched air, or argon are utilized to minimize the risk of fire or explosion due to ignition of flammable vapors and to minimize undesirable oxidation of the drug, concentration enhancing polymer, or other materials in the dispersion. The temperature of the drying gas at the gas inlet of the apparatus is typically about 60°C to about 300°C. The temperature of the product particles, drying gas, and evaporated solvent at the outlet or distal end of the collection cone typically ranges from about 0°C to about 100°C.

[0101]

[0102] A suitable solvent for the spray drying process can be any organic compound in which the active agent and the polymer are mutually soluble. The solvent should be relatively low toxic and removed from the dispersion to an acceptable level according to the International Committee on Harmonization (ICH) guidelines. Removal of the solvent to this level may require a subsequent processing step such as tray drying or secondary drying. In some embodiments, the solvent is an alcohol, a ketone, an ether, an ester, a halogenated alkane, an amide, a sulfone, an acid, or a nitro compound. In some embodiments, the solvent is methanol, ethanol, n-propanol, isopropanol, or butanol. In some embodiments, the solvent is acetone, methyl ethyl ketone (MEK), or methyl isobutyl ketone (MIBK). In some embodiments, the solvent is methyl acetate, ethyl acetate, or propyl acetate. In some embodiments, the solvent is diethyl ether, tetrahydrofuran (THF), 2-methyl THF, 2,5-dimethyl THF, or 2,2,5,5-tetramethyl THF. In some embodiments, the solvent is acetonitrile, methylene chloride, toluene, 1,1,1-trichloroethane, dimethylacetamide (DMA), nitromethane, acetic acid, or dimethylsulfoxide (DMSO). Mixtures of solvent and water are suitable as long as the polymer and compound of formula (I) are sufficiently soluble to make a spray-drying process practical. In some embodiments, the water:solvent mixture is water:acetone. In some embodiments, the water:solvent mixture is water:THF. In some embodiments, the water:solvent mixture is water:methanol. In some embodiments, the water:solvent mixture is water:ethanol. In some embodiments, the water:solvent mixture is water:methyl ethyl ketone. In some embodiments, the water:solvent mixture is water:ethyl acetate. In some embodiments, the water:solvent mixture is water:methylene chloride. In some embodiments, mixtures of solvents are suitable as long as the polymer and compound of formula (I) are sufficiently soluble to make a spray-drying process practical. In some embodiments, the solvent:solvent mixture is methanol:ethyl acetate. In some embodiments, the solvent is a solvent mixture ethanol:ethyl acetate.In some embodiments, the solvent:solvent mixture is methanol:dichloromethane. In some embodiments, the solvent:solvent mixture is ethanol:dichloromethane.

[0102]

[0103] The composition of the solvent-borne feed depends on the desired ratio of drug to polymer in the dispersion and the solubility of the drug and polymer in the solvent. In general, it is desirable to have as high a concentration of the combined drug and polymer in the solvent-borne feed as possible, provided that the drug and polymer are dissolved in the solvent at the temperature range of the process to reduce the total amount of solvent that needs to be removed to form a solid amorphous dispersion. In some embodiments, the solvent-borne feed has a combined drug and polymer concentration of at least about 0.01% to at least about 20% by weight. In some embodiments, the solvent-borne feed has a combined drug and polymer concentration of at least about 0.01% by weight. In some embodiments, the solvent-borne feed has a combined drug and polymer concentration of at least about 0.1% by weight. In some embodiments, the solvent-borne feed has a combined drug and polymer concentration of at least about 0.5% by weight. In some embodiments, the solvent-borne feed has a combined drug and polymer concentration of at least about 1.0% by weight. In some embodiments, the solvent-borne feed has a combined drug and polymer concentration of at least about 2.0% by weight. In some embodiments, the solvent-borne feed has a combined drug and polymer concentration of at least about 3.0% by weight. The solvent-borne feed has a combined drug and polymer concentration of at least about 4.0% by weight. In some embodiments, the solvent-borne feed has a combined drug and polymer concentration of at least about 5.0% by weight. In some embodiments, the solvent-borne feed has a combined drug and polymer concentration of at least about 6.0% by weight. In some embodiments, the solvent-borne feed has a combined drug and polymer concentration of at least about 7.0% by weight. In some embodiments, the solvent-borne feed has a combined drug and polymer concentration of at least about 8.0% by weight. In some embodiments, the solvent-borne feed has a combined drug and polymer concentration of at least about 9.0% by weight. In some embodiments, the solvent-borne feed has a combined drug and polymer concentration of at least about 10.0% by weight.

[0103]

[0104] The average residence time of the particles in the drying chamber should be at least 10 seconds, preferably at least 20 seconds. Typically, after solidification, the formed powder remains in the spray drying chamber for about 5-60 seconds to allow further evaporation of the solvent. The final solvent content of the solid dispersion upon exiting the dryer should be low to reduce the mobility of the drug molecules in the dispersion, thereby improving stability. Generally, the solvent content of the dispersion upon leaving the spray drying chamber should be less than about 10% by weight. In some embodiments, the solvent content of the dispersion upon leaving the spray drying chamber is less than about 9% by weight. In some embodiments, the solvent content of the dispersion upon leaving the spray drying chamber is less than about 8% by weight. In some embodiments, the solvent content of the dispersion upon leaving the spray drying chamber is less than about 7% by weight. In some embodiments, the solvent content of the dispersion upon leaving the spray drying chamber is less than about 6% by weight. In some embodiments, the solvent content of the dispersion when it leaves the spray drying chamber is less than about 5% by weight. In some embodiments, the solvent content of the dispersion when it leaves the spray drying chamber is less than about 4% by weight. In some embodiments, the solvent content of the dispersion when it leaves the spray drying chamber is less than about 3% by weight. In some embodiments, the solvent content of the dispersion when it leaves the spray drying chamber is less than about 2% by weight. In some embodiments, the solvent content of the dispersion when it leaves the spray drying chamber is less than about 1% by weight. In some embodiments, the acetone content of the dispersion when it leaves the spray drying chamber is less than about 0.5% by weight. In some embodiments, the acetone content of the dispersion when it leaves the spray drying chamber is less than about 0.3% by weight. In some embodiments, the acetone content of the dispersion when it leaves the spray drying chamber is less than about 0.1% by weight. Subsequent processing steps such as tray drying may be used to remove the solvent to this level.

[0104] Hot Melt Dispersion

[0105] Dispersions of active agents and pharma- ceutically acceptable polymers described herein can be made by hot-melt extrusion.In one embodiment, a process is provided herein for preparing a solid dispersion comprising an amorphous or substantially amorphous form of a compound of formula (I), the process comprising: (a) metering and dispensing a compound of formula (I), one or more polymers, and optionally one or more additional additives (e.g., plasticizers); (b) mixing the compound of formula (I), the polymers, and the additional additives in a mixer; (c) feeding the mixed material at a controlled speed and at a controlled temperature into a hot-melt extruder; (d) cooling the extruded material; (e) recovering the cooled hot-melt extruded material; and (f) grinding or milling the extruded material to a suitable form for mixing with additional pharmaceutical excipients.In some embodiments, the hot-melt extrudate of the compound of formula (I) is prepared in a heated screw hot-melt extruder at a controlled speed and temperature. In some embodiments, the hot melt extrudate of the compound of formula (I) is prepared at a controlled temperature of 130° C. to 180° C. In some embodiments, the one or more polymers of the hot melt extrudate of the compound of formula (I) is hydroxypropyl methylcellulose acetate succinate. In embodiments, the one or more polymers of the hot melt extrudate of the compound of formula (I) are vinylpyrrolidinone-vinyl acetate copolymers (e.g., Kollidon® VA64, etc.). In some embodiments, the solid dispersion of the hot melt extrudate of the compound of formula (I) comprises about 10% to about 50% by weight of the compound of formula (I) based on the total weight of the hot melt extrudate. In some embodiments, the solid dispersion of the hot melt extrudate of the compound of formula (I) comprises about 10% to about 40% by weight of the compound of formula (I) based on the total weight of the hot melt extrudate. In some embodiments, the solid dispersion of the hot melt extrudate of the compound of formula (I) comprises about 10% to about 30% by weight of the compound of formula (I) based on the total weight of the hot melt extrudate. In some embodiments, the solid dispersion of the hot melt extrudate of the compound of formula (I) comprises about 20% to about 30% by weight of the compound of formula (I) based on the total weight of the hot melt extrudate.

[0105]

[0106] In some embodiments, the one or more additional additives are plasticizers. In some embodiments, the additive in the hot melt extrudate of the compound of formula (I) comprises PEG400. In some embodiments, the additive in the hot melt extrudate of the compound of formula (I) comprises PEG1500. In some embodiments, the additive in the hot melt extrudate of the compound of formula (I) comprises Vitamin E TPGS. In some embodiments, the additive in the hot melt extrudate of the compound of formula (I) comprises Labrasol. In some embodiments, the additive in the hot melt extrudate of the compound of formula (I) comprises Pluronic P407. In some embodiments, the hot melt extrudate of the compound of formula (I) comprises about 5% to about 30% by weight of the compound of formula (I) based on the total weight of the hot melt extrudate consisting of the polymer and the plasticizer. In some embodiments, the hot melt extrudate of the compound of formula (I) comprises about 10% to about 30% by weight of the compound of formula (I) based on the total weight of the hot melt extrudate consisting of the polymer and the plasticizer. In some embodiments, the hot melt extrudate of the compound of formula (I) comprises about 20% to about 30% by weight of the compound of formula (I), based on the total weight of the hot melt extrudate consisting of the polymer and the plasticizer.

[0106]

[0107] In some embodiments, a hot melt extrudate of the compound of formula (I) comprising about 25% compound of formula (I), about 20% PEG1500, and about 55% VA64 may be extruded at about 160°C.

[0107]

[0108] In some embodiments, the dispersion is prepared by mixing all the individual components in a suitable mixer, such as a blender, shaker, V-blender, or mill, feeding the mixed material into a hot melt extruder at a controlled speed and temperature, cooling the extruded material in air, or by gas flow, or in a pool of liquid, or on a surface or moving belt, and collecting the cooled hot melt extrusion material.In some embodiments, the hot melt extrusion material is used as is.In some embodiments, the hot melt extrusion material is adapted to a formulation for controlled delivery of the compound of formula (I).

[0108]

[0109] In some embodiments, the dispersion is prepared by mixing one or more of the individual components in a suitable mixer, such as a blender, shaker, V-blender, or mill; adding one or more of the individual components to a hot melt extruder at a controlled speed and temperature during the extrusion process; cooling the extruded material in air, or by gas flow, or in a pool of liquid, or on a surface or moving belt; and collecting the cooled hot melt extrusion material. In some embodiments, the hot melt extrusion material may be used as is. In some embodiments, the hot melt extrusion material may be adapted to a formulation for controlled delivery of the compound of formula (I).

[0109] Pharmaceutical Compositions and Formulations

[0110] In one aspect, also provided herein is a pharmaceutical composition comprising an amorphous form of the compound of formula (I) having a purity by HPLC of greater than 95% and one or more pharma- ceutically acceptable carriers, excipients, or diluents. In one aspect, also provided herein is a pharmaceutical composition comprising an amorphous form of the compound of formula (I) having a purity by HPLC of greater than 95% and one or more pharma- ceutically acceptable carriers, excipients, or diluents and polymers. In one aspect, provided herein is a pharmaceutical composition comprising an amorphous form of the compound of formula (I) containing no more than 5% (w / w) of any crystalline form or no detectable amount of any crystalline form and one or more pharma- ceutically acceptable carriers, excipients, or diluents.

[0110]

[0111] For example, such compositions or pharmaceutical compositions may be in the form of tablets, capsules, pills, powders, liquids, suspensions, emulsions, granules, sustained release formulations, solutions, suspensions, etc. The pharmaceutical composition may be an oral formulation suitable for single administration of a precise dose.

[0111]

[0112] The amorphous form of the compound of formula (I) may be formulated into a final dosage form, which may include one or more of a liquid, solid, or semi-solid dosage form, depending on the route of administration.

[0112]

[0113] Excipients employed in pharmaceutical compositions can impart good powder flow and compression properties to the material being compressed. Desirable properties of excipients can include high compressibility so that strong tablets can be made at low compression forces, good powder flow properties that can improve the powder flow of other excipients in the composition, and cohesiveness to prevent tablets from crumbling during processing, shipping, and handling, for example. Such properties are imparted to these excipients through pre-processing steps such as dry granulation (e.g., by roller compaction, slugging), wet granulation, spray drying spheronization (e.g., spray dried dispersions, solid nanodispersions), or crystallization (e.g., salt forms) of the pharmaceutical composition. They may be classified according to their role in the final tablet. Other excipients that impart physical properties to the finished tablet are colorants and flavoring agents (e.g., in the case of chewable tablets). Examples of excipients can be found, for example, in the Handbook of Pharmaceutical Excipients (5 th edition) (Edited by Raymond C. Rowe, Paul J. Sheskey, and Sian C. Owen, Published by: Pharmaceutical Press.)

[0113]

[0114] As described herein, the pharmaceutical composition may also include a pharma- ceutically acceptable polymer. The pharma-ceutically acceptable polymer may be ionic or non-ionic. Exemplary pharma-ceutically acceptable polymers include polyvinylpyrrolidone, polyethylene oxide, polyethylene glycol, poly(vinylpyrrolidone-co-vinyl acetate), polyoxyethylene-polyoxypropylene block copolymers, graft copolymers of polyethylene glycol with polyvinylcaprolactam and polyvinyl acetate, polymethacrylates, polyoxyethylene alkyl ethers, polyoxyethylene castor oil, polycaprolactam, polylactic acid, polyglycolic acid, poly(lactic-glycolic) acid, lipids, cellulose, pullulan, dextran, maltodextrin, hyaluronic acid, polysialic acid, chondroitin sulfate, heparin, fucosyl esters, glycer ... Idan, polysulfate pentosan, spirulan, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose propionate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, methylcellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, carboxymethylethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate phthalate, hydroxypropyl methylcellulose propionate phthalate, hydroxypropyl methylcellulose acetate trimellitate, pro Hydroxypropyl methylcellulose trimellitate, Cellulose acetate succinate, Methylcellulose acetate succinate, Dextran, Dextran acetate, Dextran tropionate, Dextran succinate, Dextran acetate propionate, Dextran acetate succinate, Dextran tropionate succinate, Dextran acetate propionate succinate, Poly(methacrylic acid-co-methyl methacrylate) 1:1, Poly(methacrylic acid-co-methyl methacrylate) 1:2, Poly(methacrylic acid Poly(butyl methacrylate-co-ethyl acrylate) 1:1, hydroxyethyl cellulose, methyl cellulose and hydroxypropyl cellulose, polymethacrylic acid-ethyl acrylate, polymethacrylic acid-methyl methacrylate, polymethyl methacrylate-ethyl acrylate, polytrimethylammonioethyl methacrylate, methyl methacrylate-ethyl acrylate and poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate), or mixtures thereof.In some embodiments, the pharma- ceutically acceptable polymer is polyvinylpyrrolidone, polyethylene oxide, polyethylene glycol, poly(vinylpyrrolidone-co-vinyl acetate), polyoxyethylene-polyoxypropylene block copolymers, graft copolymers (composed of polyethylene glycol, polyvinylcaprolactam, and polyvinyl acetate), polymethacrylates, polyoxyethylene alkyl ethers, polyoxyethylene castor oil, polycaprolactam, polylactic acid, polyglycolic acid, poly(lactic-glycolic) acid, lipids, cellulose, pullulan, dextran, maltodextrin, hyaluronic acid, polysialic acid, chondroitin sulfate, heparin, fucoidan, pentosan polysulfate, spirulan, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose propionate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, methylcellulose acetate phthalate. , hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, carboxymethyl ethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate phthalate, hydroxypropyl methylcellulose propionate phthalate, hydroxypropyl methylcellulose acetate trimellitate, hydroxypropyl methylcellulose propionate, cellulose acetate succinate, methyl cellulose acetate succinate, dextran, dextran acetate, dextran tropionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran tropionate succinate, dextran acetate propionate succinate, poly(methacrylic acid-co-methyl methacrylate) 1:1, poly(methacrylic acid-co-methyl methacrylate) 1:2, poly(methacrylic acid-co-ethyl acrylate) 1:1, and mixtures thereof. In some embodiments, the pharma- ceutically acceptable polymer is hydroxypropyl methylcellulose acetate succinate.

[0114]

[0115] The pharmaceutical compositions provided herein may include one or more fillers, added, for example, to increase the bulk weight of the blend resulting in a practical size for compression. Fillers that may be used include calcium salts, such as dibasic calcium phosphate, and one or more of sugars, such as lactose, sucrose, dextrose, microcrystalline cellulose, mannitol, and maltodextrin. Examples of pharmaceutically acceptable fillers and pharmaceutically acceptable diluents include, but are not limited to, powdered sugar, compressed sugar, dextrates, dextrin, dextrose, lactose, mannitol, microcrystalline cellulose, powdered cellulose, sorbitol, sucrose, and talc. In some embodiments, the filler is microcrystalline cellulose, which can be produced by controlled hydrolysis of alpha cellulose. Suitable microcrystalline cellulose will have an average particle size of about 20 nm to about 200 nm. Suitable microcrystalline celluloses include, for example, Avicel PH 101, Avicel PH 102, Avicel PH 103, Avicel PH 105, and Avicel PH 200, manufactured by FMC Corporation. In an embodiment, the filler is lactose.

[0115]

[0116] The pharmaceutical composition may also include a lubricant. As used herein, the term "lubricant" is typically added to prevent tableting materials from sticking to the punches, minimize friction during tablet compression, and allow the compressed tablet to be removed from the die. Examples of lubricants include, but are not limited to, colloidal silica, magnesium trisilicate, talc, magnesium carbonate, magnesium oxide, glycerylbehaptate, polyethylene glycol, ethylene oxide polymers (e.g., Carowax), sodium lauryl sulfate, magnesium stearate, aluminum stearate, calcium stearate, sodium stearyl fumarate, stearic acid, magnesium lauryl stearate, and a mixture of magnesium stearate and sodium lauryl sulfate. Exemplary lubricants include calcium stearate, magnesium stearate, and sodium stearyl fumarate. In some embodiments, the lubricant is magnesium stearate.

[0116]

[0117] The pharmaceutical compositions provided herein may also include a lubricant. As used herein, the term "lubricant" is a substance added to a powder that can improve its flowability, such as by reducing interparticle friction. Exemplary lubricants include, but are not limited to, colloidal silica, colloidal silicon dioxide, fumed silica, CAB-O-SIL® M-5P, AEROSIL®, talc, Syloid®, starch, and magnesium aluminum silicate. In some embodiments, the lubricant is silicon dioxide. It should be noted that an excipient may serve multiple functions. In some embodiments, a lubricant, such as magnesium stearate, may also function as a lubricant.

[0117]

[0118] Disintegrants may be present in an amount necessary to accelerate dissolution (e.g., increase the rate of tablet disintegration). As used herein, the term "disintegrant" refers to an excipient that can counter the physical forces of particle binding in a tablet or capsule when the oral formulation is placed in an aqueous environment. Disintegrants include starch derivatives and salts of carboxymethylcellulose. Examples of pharmaceutically acceptable disintegrants include, but are not limited to, starches, such as sodium starch glycolate, pregelatinized starch, clays, cellulose, alginates, gums, cross-linked polymers, such as cross-linked polyvinylpyrrolidone (e.g., Polyplasdone™, polyvinylpolypyrrolidone, crospovidone, cross-linked calcium carboxymethylcellulose, and cross-linked sodium carboxymethylcellulose (croscarmellose sodium), and polysaccharides. In some embodiments, the disintegrant is crospovidone (e.g., PVP-XL).

[0118]

[0119] Also provided herein is a solid dispersion comprising a pharmaceutical composition comprising an amorphous form of the compound of formula (I) having a purity by HPLC of greater than 95% and a polymer in admixture with one or more pharma- ceutically acceptable carriers, excipients, or diluents. In some embodiments, an amorphous solid dispersion is provided comprising an amorphous form of the compound of formula (I) having a purity by HPLC of greater than 95%, a polymer, and one or more pharmaceutical carriers, excipients, or diluents. In some embodiments, a solid dispersion is provided comprising an amorphous form of the compound of formula (I) and a polymer, the solid dispersion being essentially free of crystalline forms of the compound of formula (I). In some embodiments, a solid dispersion is provided herein comprising an amorphous form of the compound of formula (I), a polymer, and one or more pharma- ceutically acceptable carriers, excipients, or diluents, the solid dispersion comprising no more than 5% (w / w) of any crystalline form or no detectable amount of any crystalline form.

[0119]

[0120] In some embodiments, the present disclosure provides a method for producing a composition having a purity of greater than 95% by HPLC. A pharmaceutical composition is described that includes a solid dispersion comprising an amorphous form of the compound represented by formula (I) having the formula: In some embodiments, a pharmaceutical composition is provided that includes an amorphous form of the compound of formula (I) and a polymer, the solid dispersion being essentially free of crystalline forms of the compound of formula (I). In some embodiments, a pharmaceutical composition is provided that includes an amorphous form of the compound of formula (I) that includes no more than 5% (w / w) of any crystalline form or does not include a detectable amount of any crystalline form, and a pharma- ceutically acceptable polymer.

[0120]

[0121] In some embodiments, the solid dispersion comprises about 10% to about 50% by weight, or about 10% to about 30% by weight, or about 20% to about 30% by weight of the compound represented by Formula (I) based on the total weight of the solid dispersion. In some embodiments, the pharmaceutical composition may comprise about 25% by weight of the compound represented by Formula (I) based on the total weight of the solid dispersion.

[0121]

[0122] Exemplary pharma- ceutically acceptable polymers include polyvinylpyrrolidone, polyethylene oxide, polyethylene glycol, poly(vinylpyrrolidone-co-vinyl acetate), polyoxyethylene-polyoxypropylene block copolymers, graft copolymers of polyethylene glycol with polyvinyl caprolactam and polyvinyl acetate, polymethacrylates, polyoxyethylene alkyl ethers, polyoxyethylene castor oil, polycaprolactam, polylactic acid, polyglycolic acid, poly(lactic-glycolic) acid, lipids, cellulose, pullulan, dextran, maltodextrin, hyaluronic acid, polysialic acid, chondroitin sulfate, heparin, fucoidan, pentosan polysulfate, spirulan, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose propionate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, methylcellulose acetate phthalate, hydroxypropyl ... cellulose acetate terephthalate, cellulose acetate isophthalate, carboxymethylethylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate phthalate, hydroxypropylmethylcellulose propionate, hydroxypropylmethylcellulose acetate trimellitate, hydroxypropylmethylcellulose propionate, cellulose acetate succinate, methylcellulose acetate succinate, dextran, dextran acetate, dextran tropionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran tropionate succinate, dextran acetate propionate succinate, poly(methacrylic acid-co-methyl methacrylate) 1:1, poly(methacrylic acid-co-methyl methacrylate) 1:2, poly(methacrylic acid-co-ethyl acrylate) 1:1, or mixtures thereof. For example, a pharma- ceutically acceptable polymer in the formulations provided herein is hydroxypropyl methylcellulose acetate succinate.

[0122]

[0123] In some embodiments, described herein are pharma- ceutically acceptable compositions for oral administration, the compositions comprising: (i) a solid dispersion, the solid dispersion comprising an amorphous form of a compound represented by formula (I): [ka] and a pharma- ceutically acceptable polymer; and (ii) one or more pharma-ceutically acceptable excipients.

[0123]

[0124] In some embodiments, the solid dispersion comprises no more than about 5% w / w of any crystalline form of the compound. In some embodiments, the solid dispersion comprises substantially no detectable amount of any crystalline form of the compound. In some embodiments, the amorphous form has a powder X-ray diffraction pattern substantially as shown in FIG. 1. In some embodiments, the composition comprises no more than about 5% (w / w) of any crystalline form of the compound in the aggregates when exposed to 60% relative humidity at 25° C. for 1 month, 3 months, or 6 months. In some embodiments, the composition comprises no more than about 5% (w / w) of any crystalline form of the compound in the aggregates when exposed to 75% relative humidity at 40° C. for 1 month, 3 months, or 6 months. In some embodiments, the pharma- ceutically acceptable composition comprises about 10% to about 30% by weight of the compound, based on the total weight of the solid dispersion. In some embodiments, the pharma- ceutically acceptable composition comprises about 20% to about 30% by weight of the compound, based on the total weight of the solid dispersion. In some embodiments, the pharma- ceutically acceptable composition comprises about 25% by weight of the compound, based on the total weight of the solid dispersion.In some embodiments, the pharma- ceutically acceptable polymer is selected from the group consisting of polyvinylpyrrolidone, polyethylene oxide, polyethylene glycol, poly(vinylpyrrolidone-co-vinyl acetate), polyoxyethylene-polyoxypropylene block co-carriers, grafted co-carriers (composed of polyethylene glycol, polyvinylcaprolactam and polyvinyl acetate), polymethacrylates, polyoxyethylene alkyl ethers, polyoxyethylene castor oil, polycaprolactam, polylactic acid, polyglycolic acid, poly(lactic-glycolic) acid, lipids, cellulose, pullulan, dextran, maltodextrin, hyaluronic acid, polysialic acid, chondroitin sulfate, heparin, fucoidan, pentosan polysulfate, spirulan, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose propionate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, methylcellulose acetate phthalate, The polymer is selected from the group consisting of hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, carboxymethylethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate phthalate, hydroxypropyl methylcellulose propionate phthalate, hydroxypropyl methylcellulose acetate trimellitate, hydroxypropyl methylcellulose propionate trimellitate, cellulose acetate succinate, methylcellulose acetate succinate, dextran, dextran acetate, dextran tropionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran acetate propionate succinate, poly(methacrylic acid-co-methyl methacrylate) 1:1, poly(methacrylic acid-co-methyl methacrylate) 1:2, poly(methacrylic acid-co-ethyl acrylate) 1:1, or mixtures thereof. In some embodiments, the pharma-ceutically acceptable polymer is hydroxypropyl methylcellulose acetate succinate. In some embodiments, the compound and the pharma- ceutically acceptable polymer are present in a ratio of compound:polymer of about 40:60 to about 10:90.In some embodiments, the compound and the pharma- ceutically acceptable polymer are present in a compound:polymer ratio of about 30:70 to about 20:80. In some embodiments, the compound and the pharma- ceutically acceptable polymer are present in a compound:polymer ratio of about 25:75. In some embodiments, the solid dispersion is a solid spray-dried dispersion. In some embodiments, the solid dispersion has a solubility in water at pH 6.5 of about 100 μg / mL at 25°C to about 200 μg / mL at 25°C. In some embodiments, the solid dispersion has a solubility in water at pH 6.5 of about 120 μg / mL at 25°C. In some embodiments, the solid dispersion has a solubility in water at pH 2 of about 150 μg / mL at 25°C to about 300 μg / mL at 25°C. In some embodiments, the solid dispersion has a solubility in water at pH 2 of about 178 μg / mL at 25°C.

[0124]

[0125] In some embodiments, the pharma- ceutically acceptable composition comprises less than about 10% by weight of the compound represented by Formula (II), based on the weight of the compound of Formula (I). [ka]

[0125]

[0126] In some embodiments, the pharma- ceutically acceptable composition comprises less than about 3% by weight of the compound represented by Formula (II), based on the weight of the compound of Formula (I). [ka]

[0126]

[0127] In some embodiments, the pharma- ceutically acceptable composition comprises less than about 1% by weight of the compound represented by Formula (II), based on the weight of the compound of Formula (I). [ka]

[0127]

[0128] In some embodiments, the pharma- ceutically acceptable composition comprises about 0.1% to about 0.5% by weight of the compound represented by Formula (II), based on the weight of the compound of Formula (I). [ka]

[0128]

[0129] In some embodiments, the pharma- ceutically acceptable composition comprises about 0.01% by weight to about 0.1% by weight of the compound represented by formula (II), based on the weight of the compound of formula (I). [ka]

[0129]

[0130] In some embodiments, the pharma- ceutically acceptable composition comprises less than about 10% by weight of the compound represented by Formula (III), based on the weight of the compound of Formula (I). [ka]

[0130]

[0131] In some embodiments, the pharma- ceutically acceptable composition comprises less than about 3% by weight of the compound represented by Formula (III), based on the weight of the compound of Formula (I). [ka]

[0131]

[0132] In some embodiments, the pharma- ceutically acceptable composition comprises less than about 3% by weight of the compound represented by Formula (III), based on the weight of the compound of Formula (I). [ka]

[0132]

[0133] In some embodiments, the pharma- ceutically acceptable composition comprises less than about 1% by weight of the compound represented by Formula (III), based on the weight of the compound of Formula (I). [ka]

[0133]

[0134] In some embodiments, the pharma- ceutically acceptable composition comprises about 0.1% to about 0.5% by weight of the compound represented by Formula (III), based on the weight of the compound of Formula (I). [ka]

[0134]

[0135] In some embodiments, the pharma- ceutically acceptable composition comprises about 0.01% to about 0.1% by weight of the compound represented by Formula (III), based on the weight of the compound of Formula (I). [ka]

[0135]

[0136] In another embodiment, the present specification provides a compound represented by formula (I): [ka] and a pharma- ceutically acceptable excipient, wherein greater than about 96% by weight of the compound present in the pharma- ceutically acceptable composition is in amorphous form.

[0136]

[0137] In some embodiments, the amorphous form has a characteristic amorphous X-ray powder diffraction halo pattern. In some embodiments, the amorphous form has an X-ray powder diffraction pattern substantially as shown in FIG.

[0137]

[0138] In some embodiments, the powder X-ray diffraction spectrum is measured using Cu Kα radiation. In some embodiments, the amorphous form of the compound has a glass transition temperature of about 125° C. In some embodiments, the composition does not contain a detectable amount of any crystalline form of the compound of Formula (I).

[0138]

[0139] In one embodiment, described herein is a pharma- ceutically acceptable composition for orally delivering 50 mg of a compound represented by formula (I) to a patient, [ka] This includes an intragranular blend, the intragranular blend comprising a solid dispersion having 50 mg of a compound, the compound being present in amorphous form (hydroxypropylmethylcellulose acetate succinate), an intragranular blend comprising a bulking agent and / or filler, a lubricant and / or glidant, and an extragranular blend comprising a lubricant and / or glidant.

[0139]

[0140] In one embodiment, described herein is a pharma- ceutically acceptable composition for orally delivering 50 mg of a compound represented by formula (I) to a patient, [ka] This includes a solid dispersion having 50 mg of a compound, where the compound is present in amorphous form, hydroxypropyl methylcellulose acetate succinate, a bulking agent, filler, and a lubricant and / or glidant.

[0140]

[0141] In some embodiments, the solid dispersion comprises an amorphous form of the compound represented by Formula (I) and a pharma- ceutically acceptable polymer in a ratio of about 40:60 to about 10:90, or about 30:70 to about 20:80. In some embodiments, the amorphous form of the compound represented by Formula (I) and a pharma- ceutically acceptable polymer may be in a ratio of about 25:75.

[0141]

[0142] Also provided herein is a pharmaceutical composition comprising: (a) an intragranular blend comprising (i) a solid spray-dried dispersion comprising a compound represented by Formula (I) and a pharma- ceutically acceptable polymer, (ii) one or more fillers, (iii) a disintegrant, (iv) a glidant, and (v) a lubricant; and (b) an extragranular blend comprising (i) a glidant, and (ii) a lubricant.

[0142]

[0143] In some embodiments, the blend of intragranular and extragranular blends is in a ratio of about 90:10 to about 99.5:0.5. For example, the blend of intragranular and extragranular blends may be in a ratio of about 99:1.

[0143]

[0144] In some embodiments, the solid dispersion of the intragranular blend comprises about 10% to about 50%, or about 10% to about 30%, or about 20% to about 30% by weight of the amorphous form of the compound represented by Formula (I), based on the total weight of the solid spray dried dispersion. In some embodiments, the solid spray dried dispersion may comprise about 25% by weight of the amorphous form of the compound represented by Formula (I), based on the total weight of the solid spray dried dispersion.

[0144]

[0145] In some embodiments, the composition of the agent is selected from the group consisting of polyvinylpyrrolidone, polyethylene oxide, polyethylene glycol, poly(vinylpyrrolidone-co-vinyl acetate), polyoxyethylene-polyoxypropylene block copolymers, graft copolymers (composed of polyethylene glycol, polyvinylcaprolactam and polyvinyl acetate), polymethacrylates, polyoxyethylene alkyl ethers, polyoxyethylene castor oil, polycaprolactam, polylactic acid, polyglycolic acid, poly(lactic-glycolic) acid, lipids, cellulose, pullulan, dextran, maltodextrin, hyaluronic acid, polysialic acid, chondroitin sulfate, heparin, fucoidan, pentosan polysulfate, spirulan, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose propionate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, methylcellulose acetate phthalate, hydroxypropyl ... The medicament may comprise a medicamentically acceptable polymer selected from the group consisting of hydroxypropyl cellulose, cellulose acetate terephthalate, cellulose acetate isophthalate, carboxymethylethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate phthalate, hydroxypropyl methylcellulose propionate phthalate, hydroxypropyl methylcellulose acetate trimellitate, hydroxypropyl methylcellulose propionate trimellitate, cellulose acetate succinate, methylcellulose acetate succinate, dextran, dextran acetate, dextran tropionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran acetate propionate succinate, poly(methacrylic acid-co-methyl methacrylate) 1:1, poly(methacrylic acid-co-methyl methacrylate) 1:2, poly(methacrylic acid-co-ethyl acrylate) 1:1, or mixtures thereof. For example, the medicamentically acceptable polymer is hydroxypropyl methylcellulose acetate succinate.

[0145]

[0146] In some embodiments, the pharmaceutical composition comprises an amorphous form of the compound represented by Formula (I) and a pharma- ceutically acceptable polymer in a ratio of about 40:60 to about 10:90, or about 30:70 to about 20:80. In some embodiments, the amorphous form of the compound represented by Formula (I) and a pharma- ceutically acceptable polymer may be in a ratio of about 25:75.

[0146]

[0147] In some embodiments, the intragranular blend of the pharmaceutical composition includes one or more fillers, and the total amount of the one or more fillers is about 40% to about 80% by weight based on the total weight of the pharmaceutical composition. The one or more fillers are lactose, maltodextrin, mannitol, microcrystalline cellulose, pregelatinized starch, sucrose esters, or hydrates thereof. In some embodiments, the intragranular blend includes two fillers. When the intragranular blend includes two fillers, each filler may be independently present in an amount of about 20% to about 40% by weight, for example about 33% by weight, based on the total weight of the pharmaceutical composition. In some embodiments, one filler may be microcrystalline cellulose and the other filler may be lactose monohydrate.

[0147]

[0148] In some embodiments, the intragranular blend of the pharmaceutical composition comprises about 1% to about 10% by weight, for example about 5% by weight, of a disintegrant based on the total weight of the pharmaceutical composition. The disintegrant is crospovidone, croscarmellose sodium, sodium starch glycolate, microcrystalline cellulose, or pregelatinized starch. In some embodiments, the disintegrant in the intragranular blend may be crospovidone.

[0148]

[0149] In some embodiments, the lubricant of the intragranular blend is present in an amount of about 0.1% to about 1%, for example about 0.5%, based on the total weight of the pharmaceutical composition. For example, the lubricant of the intragranular blend may be silicon dioxide.

[0149]

[0150] In some embodiments, the lubricant of the extragranular blend is present in an amount of about 0.1% to about 1%, for example about 0.5%, based on the total weight of the pharmaceutical composition. In some embodiments, the lubricant of the extragranular blend may be silicon dioxide.

[0150]

[0151] In some embodiments, the lubricant of the intragranular blend is present in an amount of about 0.1% to about 1%, for example about 0.5%, based on the total weight of the pharmaceutical composition. In some embodiments, the lubricant of the intragranular blend is magnesium stearate, calcium stearate, glyceryl monostearate, hydrogenated castor oil, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, zinc stearate, talc, microcrystalline cellulose, or sucrose ester. For example, the lubricant of the intragranular blend may be magnesium stearate.

[0151]

[0152] In some embodiments, the lubricant of the extragranular blend is present in an amount of about 0.1% to about 1%, for example about 0.5%, based on the total weight of the pharmaceutical composition. In some embodiments, the lubricant of the extragranular blend is magnesium stearate, calcium stearate, glyceryl monostearate, hydrogenated castor oil, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, zinc stearate, talc, microcrystalline cellulose, or sucrose esters. As an example, the lubricant of the extragranular blend may be magnesium stearate.

[0152]

[0153] In some embodiments, provided herein is (a) an intragranular blend comprising: (i) about 33% by weight of a solid spray dried dispersion based on the total weight of the pharmaceutical composition, the solid spray dried dispersion comprising an amorphous form of the compound represented by Formula (I) having an HPLC purity of greater than 95% and hydroxypropylmethylcellulose acetate succinate, the solid spray dried dispersion comprising about 25% by weight of the compound represented by Formula (I) based on the total weight of the solid spray dried dispersion; (ii) about 30% by weight of microcrystalline cellulose based on the total weight of the pharmaceutical composition; A pharmaceutical composition is provided comprising: (iii) an intragranular blend comprising about 30% by weight of lactose monohydrate, based on the total weight of the pharmaceutical composition; (iv) about 5% by weight of crospovidone, based on the total weight of the pharmaceutical composition; (v) about 0.5% by weight of silicon dioxide, based on the total weight of the pharmaceutical composition; and (vi) about 0.5% by weight of magnesium stearate, based on the total weight of the pharmaceutical composition; and (b) an extragranular blend comprising: (i) about 0.5% by weight of silicon dioxide, based on the total weight of the pharmaceutical composition; and (ii) about 0.5% by weight of magnesium stearate, based on the total weight of the pharmaceutical composition.

[0153]

[0154] In some embodiments, provided herein is a method for preparing a method for preparing a compound represented by formula (I), comprising: (a) an intragranular blend comprising: (i) about 200 mg of a solid spray-dried dispersion comprising an amorphous form of a compound represented by formula (I) and hydroxypropyl methylcellulose acetate succinate; wherein the solid spray-dried dispersion comprises about 50 mg of a compound represented by formula (I); A pharmaceutical composition is provided that includes: (ii) an intragranular blend comprising about 179 mg of microcrystalline cellulose, (iii) about 179 mg of lactose monohydrate, (iv) about 30 mg of crospovidone, (v) about 3 mg of silicon dioxide, and (vi) about 3 mg of magnesium stearate; and (b) an extragranular blend comprising: (i) about 3 mg of silicon dioxide, and (ii) about 3 mg of magnesium stearate.

[0154] tablet

[0155] The pharmaceutical composition may also be provided as a tablet. The tablet may be uncoated, filmed, or sugar-coated, split, embossed, plain, layered, or sustained release. It may be made in a variety of sizes, shapes, and colors. The tablet may be swallowed, chewed, or dissolved in the mouth or under the tongue.

[0155]

[0156] In one embodiment, described herein is a pharma- ceutically acceptable tablet having 50 mg of a compound represented by formula (I), [ka] It comprises an intragranular blend, the intragranular blend comprising a solid dispersion having 50 mg of a compound, the compound being present in amorphous form, which is hydroxypropyl methylcellulose acetate succinate, about 25-35% by weight of a bulking agent based on the total weight of the drug composition, about 25-35% by weight of a filler based on the total weight of the drug composition, and an extragranular blend comprising a glidant and / or lubricant. In some embodiments, the bulking agent is microcrystalline cellulose. In some embodiments, the filler is lactose or a hydrate thereof.

[0156]

[0157] In one embodiment, described herein is a pharma- ceutically acceptable tablet having 10 mg of a compound represented by formula (I), [ka] This includes an intragranular blend, the intragranular blend comprising a solid dispersion having 10 mg of a compound, the compound being present in amorphous form, which is hydroxypropyl methylcellulose acetate succinate, about 25-35% by weight of a bulking agent based on the total weight of the drug composition, about 25-35% by weight of a filler based on the total weight of the drug composition, and an extragranular blend comprising a glidant and / or lubricant. In some embodiments, the bulking agent is microcrystalline cellulose. In some embodiments, the filler is lactose. or a hydrate thereof.

[0157]

[0158] In another embodiment, provided herein is a pharma- ceutically acceptable tablet comprising 50 mg of a compound represented by formula (I): [ka] wherein the tablet comprises a solid dispersion having 50 mg of a compound, the compound being present in amorphous form, which is hydroxypropyl methylcellulose acetate succinate, about 25-35% by weight of microcrystalline cellulose, based on the total weight of the tablet, and about 25-35% by weight of lactose or a hydrate thereof, based on the total weight of the pharmaceutical composition. In some embodiments, the pharma- ceutically acceptable tablet further comprises at least one of magnesium stearate, crospovidone, and silicon dioxide. In some embodiments, the tablet comprises a solid dispersion having 50 mg of a compound, the compound being present in amorphous form, which is hydroxypropyl methylcellulose acetate succinate, based on the total weight of the tablet, and about 25-35% by weight of lactose or a hydrate thereof, based on the total weight of the pharmaceutical composition. In some embodiments, the pharma-ceutically acceptable tablet further comprises at least one of magnesium stearate, crospovidone, and silicon dioxide. In some embodiments, the tablet comprises at least one of the USP 10001-0001 for the uncoated tablet. <701> When tested using the same method, it disintegrates in less than one minute.

[0158]

[0159] In another embodiment, provided herein is a pharma- ceutically acceptable tablet comprising 10 mg of a compound represented by formula (I): [ka] wherein the tablet comprises a solid dispersion having 10 mg of a compound, the compound being present in an amorphous form, which is hydroxypropyl methylcellulose acetate succinate, about 25-35% by weight of microcrystalline cellulose, based on the total weight of the tablet, and about 25-35% by weight of lactose or a hydrate thereof, based on the total weight of the pharmaceutical composition. In some embodiments, the pharma- ceutically acceptable tablet further comprises at least one of magnesium stearate, crospovidone, and silicon dioxide. In some embodiments, the tablet is 100% by weight or more per unit weight of the USP 1000 mg of the compound for the uncoated tablet. <701> When tested using the same method, it disintegrates in less than one minute.

[0159]

[0160] In another embodiment, described herein is a pharma- ceutically acceptable composition for orally delivering 50 mg of a compound represented by formula (I), [ka] This includes an intragranular blend, the intragranular blend comprising a solid dispersion having 50 mg of a compound, the compound being present in amorphous form, the solid dispersion being hydroxypropyl methylcellulose acetate succinate, an intragranular blend comprising about 25-35% by weight of microcrystalline cellulose, about 25-35% by weight of lactose or its hydrate, based on the total amount of the drug composition, about 5% by weight of crospovidone, about 0.5% by weight of silicon dioxide, based on the total amount of the drug composition, and about 0.5% by weight of magnesium stearate, based on the total amount of the drug composition, and an extragranular blend comprising about 0.5% by weight of silicon dioxide, based on the total amount of the drug composition, and (ii) about 0.5% by weight of magnesium stearate, based on the total amount of the drug composition. In some embodiments, the composition or tablet releases at least 80% of the compound after 10 to 40 minutes when the composition is tested using a USP Apparatus II (paddle method) at 37° C. and a paddle speed of 75 rpm in 900 mL of sodium acetate buffer at pH 4.5. In some embodiments, the composition or tablet releases at least 80% of the compound after 10 minutes when the composition is tested using a USP Apparatus II (paddle method) at 37° C. and a paddle speed of 75 rpm in 900 mL of sodium acetate buffer at pH 4.5. In some embodiments, the composition or tablet releases at least 80% of the compound after 20 minutes when the composition is tested using a USP Apparatus II (paddle method) at 37° C. and a paddle speed of 75 rpm in 900 mL of sodium acetate buffer at pH 4.5. In some embodiments, the composition or tablet releases at least 80% of the compound after 30 minutes when the composition is tested using a USP Apparatus II (paddle method) at 37° C. and a paddle speed of 75 rpm in 900 mL of sodium acetate buffer at pH 4.5. In some embodiments, the composition or tablet releases at least 80% of the compound after 40 minutes when the composition is tested using a USP Apparatus II (paddle method) at 37° C. and a paddle speed of 75 rpm in 900 mL of sodium acetate buffer at pH 4.5.

[0160]

[0161] In some embodiments, provided herein is a tablet providing about 50 mg of an amorphous form of a compound represented by formula (I), the tablet comprising: (a) an intragranular blend comprising: (i) about 195 mg to about 205 mg of a solid spray-dried dispersion comprising about 50 mg of the compound and hydroxypropylmethylcellulose acetate succinate; (ii) about 177 mg to about 181 mg of microcrystalline cellulose; (iii) about 177 mg to about 181 mg of lactose monohydrate; and (iv) about 28 mg to about 32 mg of crospovidone; and (b) an extragranular blend comprising: (i) about 2 mg to about 4 mg of silicon dioxide; and (ii) about 2 mg to about 4 mg of magnesium stearate. In some embodiments, the microcrystalline cellulose may be substituted with lactose. In some embodiments, the microcrystalline cellulose may be substituted with mannitol. In some embodiments, the microcrystalline cellulose may be substituted with modified starch.

[0161]

[0162] In some embodiments, the present disclosure provides a pharmaceutical composition according to formula (I) in a weight amount of about 600 mg. and (ii) about 37.7% of the total tablet weight as microcrystalline cellulose, (iii) about 37.6% of the total tablet weight as lactose monohydrate, (iv) about 6.0% of the total tablet weight as croscarmellose sodium, (v) about 0.5% of the total tablet weight as silicon dioxide, and (vi) about 0.5% of the total tablet weight as magnesium stearate, and (b) an extragranular blend comprising: (i) about 0.5% of the total tablet weight as silicon dioxide, and (ii) about 0.5% of the total tablet weight as magnesium stearate.

[0162]

[0163] In some embodiments, provided herein is a tablet providing about 25 mg of an amorphous form of the compound represented by formula (I) in a weight of about 600 mg, the tablet comprising: (a) an intragranular blend comprising: (i) about 16.7% of the total tablet weight as a solid spray dried dispersion comprising about 25 mg of the compound and hydroxypropyl methylcellulose acetate succinate; (ii) about 38.2% of the total tablet weight as microcrystalline cellulose; (iii) about 38.1% of the total tablet weight as lactose monohydrate; (iv) about 5.0% of the total tablet weight as crospovidone; (v) about 0.5% of the total tablet weight as silicon dioxide; and (vi) about 0.5% of the total tablet weight as magnesium stearate; and (b) an extragranular blend comprising: (i) about 0.5% of the total tablet weight as silicon dioxide; and (ii) about 0.5% of the total tablet weight as magnesium stearate.

[0163]

[0164] In some embodiments, provided herein is a tablet providing about 25 mg of an amorphous form of the compound represented by formula (I) at a weight of about 600 mg, the tablet comprising: (a) an intragranular blend of: (i) about 16.7% of the total tablet weight as a solid spray dried dispersion comprising about 25 mg of the compound and hydroxypropyl methylcellulose acetate succinate; (ii) about 32.7% of the total tablet weight as microcrystalline cellulose; (iii) about 32.6% of the total tablet weight as lactose monohydrate; (iv) about 6.0% of the total tablet weight as croscarmellose sodium; and (v) about 70 / 30 (i) about 0.5% of the total tablet weight as silicon dioxide, and (ii) about 0.5% of the total tablet weight as magnesium stearate; and (b) an extragranular blend comprising: (i) about 0.5% of the total tablet weight as silicon dioxide, and (ii) about 0.5% of the total tablet weight as magnesium stearate.

[0164] Treatment method

[0165] The compounds of formula (I) are broad spectrum inhibitors of c-KIT. Disorders that may be treated by the compounds of formula (I) include gastrointestinal stromal tumors (GIST), NF-1-deficient gastrointestinal stromal tumors, succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors, KIT-driven gastrointestinal stromal tumors, PDGFRA-driven gastrointestinal stromal tumors, melanoma, acute myeloid leukemia, germ cell tumors of seminoma or dysgerminoma, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, hypereosinophilic syndromes, idiopathic hypereosinophilic syndromes, chronic Eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, non-small cell lung cancer, lung cancer, glioblastoma, glioma, malignant peripheral nerve sheath sarcoma, hypereosinophilic syndrome, KIT-driven germ cell tumors (e.g., testicular germ cell), KIT-driven skin cancer, KIT-driven renal cell carcinoma, penile cancer, PDGFRA-driven penile cancer, prostate cancer, PDGFRA-driven prostate cancer, PDGFRA-driven non-melanoma skin cancer, PDGFRA-driven glioblastoma, PDGFRA-driven sarcoma, PDGFRA-driven glioblastoma, PDGFRA-driven pancreatic cancer, or vaginal cancer, prostate cancer, penile cancer, including, but not limited to, non-melanoma skin cancer, melanoma, or breast sarcoma (including, for example, vaginal cancer, prostate cancer, penile cancer, non-melanoma skin cancer, melanoma, or breast sarcoma containing a PDGFRB mutation).

[0165]

[0166] Thus, in another embodiment, provided herein is a method of treating a disease selected from the group consisting of gastrointestinal stromal tumor (GIST), KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor, melanoma, acute myeloid leukemia, seminoma or dysgerminoma germ cell tumor, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, eosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, non-small cell lung cancer in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of a composition or one or more tablets as described herein.

[0166]

[0167] Also provided herein, in another embodiment, is a method of treating a disease selected from the group consisting of gastrointestinal stromal tumor (GIST), KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor, lung cancer, glioblastoma, glioma, malignant peripheral nerve sheath sarcoma, and hypereosinophilic syndrome in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a composition or one or more tablets described herein. In some embodiments, the disease is gastrointestinal stromal tumor (GIST).

[0167]

[0168] Also provided herein, in another embodiment, is a method of treating a disease selected from the group consisting of KIT-driven germ cell tumors (e.g., testicular germ cell), KIT-driven skin cancer, or KIT-driven renal cell carcinoma, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a composition or one or more tablets described herein.

[0168]

[0169] Also provided herein, in another embodiment, is a method of treating a disease selected from the group consisting of penile cancer, PDGFRA-driven penile cancer, prostate cancer, PDGFRA-driven prostate cancer, PDGFRA-driven non-melanoma skin cancer, PDGFRA-driven glioma, PDGFRA-driven sarcoma, PDGFRA-driven glioblastoma, or PDGFRA-driven pancreatic cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a composition or one or more tablets described herein.

[0169]

[0170] Also provided herein, in another embodiment, is a method of treating a disease involving a PDGFRB mutation selected from the group consisting of vaginal cancer, prostate cancer, penile cancer, non-melanoma skin cancer, melanoma, or breast sarcoma in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a composition or one or more tablets described herein.

[0170]

[0171] In some embodiments, provided herein are methods for treating KIT and PDGFRA mutation-induced diseases in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a composition or one or more tablets described herein. In some embodiments, provided herein are methods for treating KIT and PDGFRA mutation-induced diseases in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a composition or one or more tablets described herein. In some embodiments, provided herein are methods for treating KIT or PDGFRA mutation-induced diseases, including passenger PDGFRB mutations, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a composition or one or more tablets described herein.

[0171]

[0172] In some embodiments, the present disclosure provides a method for treating gastrointestinal disorders in a patient in need of treatment. Gastrointestinal stromal tumor (GIST), KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor Methods are provided for treating a disease selected from the group consisting of melanoma (e.g., KIT-driven melanoma or PGDFRA-driven melanoma or PGDFR-driven melanoma), acute myeloid leukemia, seminoma or dysgerminoma germ cell tumors, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, childhood glioma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, eosinophilic syndrome, idiopathic eosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, and non-small cell lung cancer, comprising administering to a patient a therapeutically effective amount of a composition or one or more tablets described herein. In some embodiments, the melanoma is a cutaneous melanoma or a non-cutaneous melanoma. In some embodiments, the melanoma is a cutaneous melanoma. In some embodiments, the cutaneous melanoma is superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, or amelanotic and desmoplastic melanoma. In some embodiments, the melanoma is non-cutaneous (non-skin) melanoma. In some embodiments, the melanoma is cutaneous melanoma or non-cutaneous melanoma is intraocular melanoma or mucosal melanoma. In some embodiments, the disease is caused by the kinase activity of c-KIT and / or PDGFRA, and / or its oncogenic forms. In some embodiments, the disease is selected from the group consisting of KIT-driven germ cell tumors (e.g., testicular germ cell), KIT-driven skin cancer (e.g., KIT-driven squamous cell carcinoma, KIT-driven Merkel cell carcinoma, uveal melanoma, non-melanoma skin cancer), or KIT-driven renal cell carcinoma (e.g., renal cell carcinoma, chromophobe renal cell carcinoma). In some embodiments, the disease is selected from the group consisting of penile cancer, PDGFRA-driven penile cancer, prostate cancer, PDGFRA-driven prostate cancer, PDGFRA-driven non-melanoma skin cancer, PDGFRA-driven glioma, PDGFRA-driven sarcoma, PDGFRA-driven glioblastoma, or PDGFRA-driven pancreatic cancer. In some embodiments, the disease comprising a PDGFRB mutation is selected from the group consisting of vaginal cancer, prostate cancer, penile cancer, non-melanoma skin cancer, melanoma, or breast sarcoma.

[0172]

[0173] In another embodiment, there is also provided herein a use of a composition or tablet as described herein for the preparation of a medicament for treating a disease selected from the group consisting of gastrointestinal stromal tumor (GIST), KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor, melanoma, acute myeloid leukemia, germ cell tumors of seminoma or dysgerminoma, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, eosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, non-small cell lung cancer. In some embodiments, the preparation of a medicament for the treatment of a disease selected from the group consisting of gastrointestinal stromal tumor (GIST), KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor, lung cancer, glioblastoma, glioma, malignant peripheral nerve sheath sarcoma, and hypereosinophilic syndrome.

[0173]

[0174] The amorphous forms of the compounds of formula (I) described herein, having a purity by HPLC of greater than 95%, are broad spectrum inhibitors of c-KIT. In some embodiments, provided herein is a method of treating a disease selected from the group consisting of gastrointestinal stromal tumor (GIST), KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor, melanoma (e.g., cutaneous melanoma, non-cutaneous melanoma, KIT-driven melanoma or PGDFRA-driven melanoma or PGDFR-driven melanoma), acute myeloid leukemia, seminoma or dysgerminoma germ cell tumor, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, eosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, non-small cell lung cancer, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I) having a purity of greater than 95% by HPLC. In some embodiments, the disease is caused by the kinase activity of c-KIT and / or PDGFRA, and / or oncogenic forms thereof. In some embodiments, the disease is gastrointestinal stromal tumor (GIST). In some embodiments, the disease is KIT-driven gastrointestinal stromal tumor. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumor. In some embodiments, the disease is lung cancer. In some embodiments, the disease is glioblastoma. In some embodiments, the disease is glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is hypereosinophilic syndrome. In some embodiments, provided herein is a method of treating or preventing PDGFR kinase-mediated tumor growth of tumor progression, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I) having a purity by HPLC of greater than about 95%.

[0174]

[0175] In some embodiments, the tumor growth or progression is caused by overexpression of PDGFRα kinase, oncogenic PDGFRα missense mutations, oncogenic PDGFRα deletion mutations, oncogenic PDGFRα gene rearrangements resulting in PDGFRα fusion proteins, PDGFRα intragenic in-frame deletions, and / or oncogenic PDGFRα gene amplifications. In some embodiments, a compound of formula (I) having a purity by HPLC of greater than 95% is administered to a cancer patient, wherein the cancer is PDGFRA-driven gastrointestinal stromal tumor, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, gastrointestinal stromal tumor, malignant peripheral nerve sheath sarcoma, intimal sarcoma, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, or lymphoblastic T-cell lymphoma. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumor (GIST). In some embodiments, the disease is lung cancer. In some embodiments, the disease is glioblastoma. In some embodiments, the disease is glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is hypereosinophilic syndrome. In some embodiments, the compound of formula (I), having a purity by HPLC of greater than 95%, is administered as a single agent or in combination with other cancer targeted therapeutics, cancer targeted biologics, immune checkpoint inhibitors, or chemotherapeutic agents.

[0175]

[0176] In some embodiments, the methods of treatment described herein include administering to a subject in need thereof an amorphous form of the compound of formula (I) or a pharmaceutical composition thereof prior to surgery (as a neoadjuvant therapy). In some embodiments, the methods of treatment described herein include administering to a subject in need thereof a composition of the compound of formula (I) described herein following surgery (as an adjuvant therapy).

[0176]

[0177] The amorphous forms of the compounds of Formula (I) described herein, free of detectable amounts of any crystalline form, are broad spectrum inhibitors of c-KIT. In some embodiments, provided herein is a method of treating a disease selected from the group consisting of gastrointestinal stromal tumor (GIST), KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor, melanoma (e.g., cutaneous melanoma, non-cutaneous melanoma, KIT-driven melanoma or PGDFRA-driven melanoma or PGDFR-driven melanoma), acute myeloid leukemia, seminoma or dysgerminoma germ cell tumor, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, eosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, non-small cell lung cancer, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I) that is free of detectable amounts of any crystalline form. In some embodiments, the disease is caused by the kinase activity of c-KIT and / or PDGFRA, and / or oncogenic forms thereof. In some embodiments, the disease is gastrointestinal stromal tumor (GIST). In some embodiments, the disease is KIT-driven gastrointestinal stromal tumor. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumor. In some embodiments, the disease is lung cancer. In some embodiments, the disease is The disease is glioblastoma. In some embodiments, the disease is glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is hypereosinophilic syndrome. In some embodiments, provided herein is a method of treating or preventing PDGFR kinase-mediated tumor growth of tumor progression, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I), which does not contain a detectable amount of any crystalline form. In some embodiments, the tumor growth or tumor progression is caused by overexpression of PDGFRα kinase, oncogenic PDGFRα missense mutations, oncogenic PDGFRα deletion mutations, oncogenic PDGFRα gene rearrangements resulting in PDGFRα fusion proteins, intragenic in-frame deletions of PDGFRα, and / or oncogenic PDGFRα gene amplifications. In some embodiments, a compound of formula (I) is administered to a cancer patient, wherein the cancer is PDGFRA-driven gastrointestinal stromal tumor, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, gastrointestinal stromal tumor, malignant peripheral nerve sheath sarcoma, intimal sarcoma, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, or lymphoblastic T-cell lymphoma. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumor (GIST). In some embodiments, the disease is lung cancer. In some embodiments, the disease is glioblastoma. In some embodiments, the disease is glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is hypereosinophilic syndrome. In some embodiments, the compound of formula (I), wherein the compound of formula (I) does not contain a detectable amount of any crystalline form, is administered as a single agent or in combination with other cancer targeted therapeutics, cancer targeted biologics, immune checkpoint inhibitors, or chemotherapeutic agents.

[0177]

[0178] Amorphous forms of the compound of formula (I) containing no more than 5% (w / w) of any crystalline form or no detectable amount of any crystalline form as described herein are broad spectrum inhibitors of c-KIT. In some embodiments, the present invention is directed to a broad spectrum inhibitor of c-KIT for use in treating gastrointestinal stromal tumors (GIST), KIT-driven gastrointestinal stromal tumors, PDGFRA-driven gastrointestinal stromal tumors, melanomas (e.g., cutaneous melanoma, non-cutaneous melanoma, KIT-driven melanoma or PGDFRA-driven melanoma or PGDFR-driven melanoma), acute myeloid leukemia, seminoma or dysgerminoma germ cell tumors, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, ovarian cancer ... A method of treating a disease selected from the group consisting of pulmonary sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, or non-small cell lung cancer is provided, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) having no more than 5% (w / w) of any crystalline form, or a compound of formula (I) that does not contain a detectable amount of any crystalline form. In some embodiments, the disease is caused by the kinase activity of c-KIT and / or PDGFRA, and / or oncogenic forms thereof. In some embodiments, the disease is gastrointestinal stromal tumor (GIST). In some embodiments, the disease is KIT-driven gastrointestinal stromal tumor. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumor. In some embodiments, the disease is lung cancer. In some embodiments, the disease is glioblastoma. In some embodiments, the disease is glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is hypereosinophilic syndrome. In some embodiments, provided herein is a method of treating or preventing PDGFR kinase-mediated tumor growth of tumor progression, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), comprising no more than 5% (w / w) of any crystalline form or comprising no detectable amount of any crystalline form.In some embodiments, tumor growth or progression is due to overexpression of PDGFRα kinase, oncogenic PDGFRα missense mutations, oncogenic PDGFRα deletion mutations, oncogenic PDGFRα gene rearrangements giving rise to PDGFRα fusion proteins, intragenic in-frame deletions of PDGFRα, and / or. is caused by oncogenic PDGFRα gene amplification. In some embodiments, a compound of formula (I) is administered to a cancer patient, free of detectable amounts of any crystalline form, wherein the cancer is PDGFRA-driven gastrointestinal stromal tumor, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, gastrointestinal stromal tumor, malignant peripheral nerve sheath sarcoma, intimal sarcoma, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, or lymphoblastic T-cell lymphoma. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumor (GIST). In some embodiments, the disease is lung cancer. In some embodiments, the disease is glioblastoma. In some embodiments, the disease is glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is hypereosinophilic syndrome. In some embodiments, a compound of formula (I) containing no more than 5% (w / w) of any crystalline form or no detectable amount of any crystalline form is administered as a single agent or in combination with other cancer targeted therapeutics, cancer targeted biologics, immune checkpoint inhibitors, or chemotherapeutic agents.

[0178]

[0179] Amorphous forms of the compound of formula (I), including any crystalline form of the compound of formula (I) that is not greater than about 5% (w / w) as described herein, are broad-spectrum inhibitors of c-KIT. In some embodiments, the present invention relates to a broad-spectrum inhibitor of c-KIT, such as gastrointestinal stromal tumor (GIST), KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor, or PDGFRA-driven gastrointestinal stromal tumor. Methods are provided for treating a disease selected from the group consisting of melanoma (e.g., cutaneous melanoma, non-cutaneous melanoma, KIT-driven melanoma or PGDFRA-driven melanoma or PGDFR-driven melanoma), acute myeloid leukemia, seminoma or dysgerminoma germ cell tumor, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, eosinophilic syndrome, idiopathic eosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, or non-small cell lung cancer, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I), including a compound of formula (I) having no more than 5% (w / w) of any crystalline form. In some embodiments, the disease is gastrointestinal stromal tumor (GIST). In some embodiments, the disease is KIT-driven gastrointestinal stromal tumor. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumor. In some embodiments, the disease is lung cancer. In some embodiments, the disease is glioblastoma. In some embodiments, the disease is glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is hypereosinophilic syndrome. In some embodiments, provided herein is a method of treating or preventing PDGFR kinase-mediated tumor growth of tumor progression, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), having no more than about 5% (w / w) of the compound of Formula (I) in any crystalline form. In some embodiments, tumor growth or progression is caused by overexpression of PDGFRα kinase, oncogenic PDGFRα missense mutations, oncogenic PDGFRα deletion mutations, oncogenic PDGFRα gene rearrangements resulting in PDGFRα fusion proteins, PDGFRα intragenic in-frame deletions, and / or oncogenic PDGFRα gene amplifications.In some embodiments, a compound of formula (I) is administered to a cancer patient, wherein the cancer is PDGFRA-driven gastrointestinal stromal tumor, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, gastrointestinal stromal tumor, malignant peripheral nerve sheath sarcoma, intimal sarcoma, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, or lymphoblastic T-cell lymphoma. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumor (GIST). In some embodiments, the disease is lung cancer. In some embodiments, the disease is glioblastoma. In some embodiments, the disease is glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is hypereosinophilic syndrome. In some embodiments, the compound of formula (I) is no more than about 5% (w / w) of formula (I) in any crystalline form. Compounds of formula (I), having the compound:

[0179]

[0180] In some embodiments, an amorphous form of the compound of formula (I) having a purity by HPLC of greater than 95% is used in the preparation of a medicament for treating a disease selected from the group consisting of gastrointestinal stromal tumor (GIST), KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor, melanoma (e.g., cutaneous melanoma, non-cutaneous melanoma, KIT-driven melanoma or PGDFRA-driven melanoma or PGDFR-driven melanoma), acute myeloid leukemia, seminoma or dysgerminoma germ cell tumor, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, eosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, non-small cell lung cancer. In some embodiments, the disease is caused by kinase activity of c-KIT and / or PDGFRA, and / or oncogenic forms thereof. In some embodiments, the disease is gastrointestinal stromal tumor (GIST). In some embodiments, the disease is KIT-driven gastrointestinal stromal tumor. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumor. In some embodiments, the disease is lung cancer. In some embodiments, the disease is glioblastoma. In some embodiments, the disease is glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is hypereosinophilic syndrome. In some embodiments, an amorphous form of the compound of formula (I) having a purity by HPLC of greater than 95% is used in the preparation of a medicament for treating or preventing PDGFR kinase-mediated tumor growth of a tumor. In some embodiments, tumor growth or progression is caused by overexpression of PDGFRα kinase, oncogenic PDGFRα missense mutations, oncogenic PDGFRα deletion mutations, oncogenic PDGFRα gene rearrangements resulting in PDGFRα fusion proteins, PDGFRα intragenic in-frame deletions, and / or oncogenic PDGFRα gene amplifications.In some embodiments, the amorphous form of the compound of formula (I) having a purity by HPLC of greater than 95% is used in the preparation of a medicament for the treatment of a disease, wherein the disease is PDGFRA-driven gastrointestinal stromal tumor, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, gastrointestinal stromal tumor malignant peripheral nerve sheath sarcoma, intimal sarcoma, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, or lymphoblastic T-cell lymphoma. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumor (GIST). In some embodiments, the disease is lung cancer. In some embodiments, the disease is glioblastoma. In some embodiments, the disease is glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is hypereosinophilic syndrome.

[0180]

[0181] In some embodiments, an amorphous form of the compound of formula (I), free from detectable amounts of any crystalline form, is used in the preparation of a medicament for treating a disease selected from the group consisting of gastrointestinal stromal tumor (GIST), KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor, melanoma (e.g., cutaneous melanoma, non-cutaneous melanoma, KIT-driven melanoma or PGDFRA-driven melanoma or PGDFR-driven melanoma), acute myeloid leukemia, seminoma or dysgerminoma germ cell tumor, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, eosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, non-small cell lung cancer. In some embodiments, the disease is caused by the kinase activity of c-KIT and / or PDGFRA, and / or oncogenic forms thereof. In some embodiments, the disease is gastrointestinal stromal tumor (GIST). In some embodiments, the disease is KIT-driven gastrointestinal stromal tumor (GIST). In some embodiments, the disease is a PDGFRA-driven gastrointestinal stromal tumor. In some embodiments, the disease is a lung cancer. In some embodiments, the disease is a glioblastoma. In some embodiments, the disease is a glioma. In some embodiments, the disease is a malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is a hypereosinophilic syndrome. In some embodiments, the amorphous form of the compound of formula (I) that does not contain a detectable amount of any crystalline form is used in the preparation of a medicament for treating or preventing PDGFR kinase-mediated tumor growth of a tumor. In some embodiments, the tumor growth or tumor progression is caused by overexpression of PDGFRα kinase, oncogenic PDGFRα missense mutations, oncogenic PDGFRα deletion mutations, oncogenic PDGFRα gene rearrangements resulting in PDGFRα fusion proteins, intragenic in-frame deletions of PDGFRα, and / or oncogenic PDGFRα gene amplifications. In some embodiments, the amorphous form of the compound of formula (I), which does not contain any detectable amount of crystalline form, is used in the preparation of a medicament for the treatment of a disease, wherein the disease is PDGFRA-driven gastrointestinal stromal tumor, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, gastrointestinal stromal tumor, malignant peripheral nerve sheath sarcoma, intimal sarcoma, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, or lymphoblastic T-cell lymphoma. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumor (GIST). In some embodiments, the disease is lung cancer. In some embodiments, the disease is glioblastoma. In some embodiments, the disease is glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is hypereosinophilic syndrome.

[0181]

[0182] In some embodiments, an amorphous form of the compound of formula (I), having no more than about 5% (w / w) of any crystalline form of the compound of formula (I), is used to treat gastrointestinal stromal tumors (GIST), KIT-driven gastrointestinal stromal tumors, PDGFRA-driven gastrointestinal stromal tumors, melanoma (e.g., cutaneous melanoma, non-cutaneous melanoma, KIT-driven melanoma or PGDFRA-driven melanoma or PGDFR-driven melanoma), acute myeloid leukemia, seminoma or In some embodiments, the method is for the preparation of a medicament for treating a disease selected from the group consisting of germ cell tumors, dysgerminoma, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, childhood glioma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, and non-small cell lung cancer. In some embodiments, the disease is caused by the kinase activity of c-KIT and / or PDGFRA, and / or oncogenic forms thereof. In some embodiments, the disease is gastrointestinal stromal tumor (GIST). In some embodiments, the disease is KIT-driven gastrointestinal stromal tumor. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumor. In some embodiments, the disease is lung cancer. In some embodiments, the disease is glioblastoma. In some embodiments, the disease is glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is hypereosinophilic syndrome. In some embodiments, the amorphous form of the compound of formula (I), having no more than about 5% (w / w) of any crystalline form of the compound of formula (I), is used to prepare a medicament for treating or preventing PDGFR kinase-mediated tumor growth of a tumor. In some embodiments, the tumor growth or tumor progression is caused by overexpression of PDGFRα kinase, oncogenic PDGFRα missense mutations, oncogenic PDGFRα deletion mutations, oncogenic PDGFRα gene rearrangements resulting in PDGFRα fusion proteins, intragenic in-frame deletions of PDGFRα, and / or oncogenic PDGFRα gene amplifications.In some embodiments, an amorphous form of the compound of formula (I), having no more than about 5% (w / w) of any crystalline form of the compound of formula (I), is used in the preparation of a medicament for the treatment of a disease, wherein the disease is PDGFRA-driven gastrointestinal stromal tumor, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, gastrointestinal stromal tumor malignant peripheral nerve sheath sarcoma, intimal sarcoma, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic. In some embodiments, the disease is eosinophilic leukemia, eosinophilic acute myeloid leukemia, or lymphoblastic T-cell lymphoma. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumor (GIST). In some embodiments, the disease is lung cancer. In some embodiments, the disease is glioblastoma. In some embodiments, the disease is glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is hypereosinophilic syndrome.

[0182]

[0183] In some embodiments, the amorphous form of the compound of formula (I), which contains no more than 5% (w / w) of any crystalline form of the compound of formula (I) or does not contain a detectable amount of any crystalline form, is used in the treatment of gastrointestinal stromal tumors (GIST), KIT-driven gastrointestinal stromal tumors, PDGFRA-driven gastrointestinal stromal tumors, melanoma (e.g., cutaneous melanoma, non-cutaneous melanoma, KIT-driven melanoma or PGDFRA-driven melanoma or PGDFR-driven melanoma), acute bone marrow tumors, osteoporosis ... The present invention is used for the preparation of a medicament for treating a disease selected from the group consisting of myeloid leukemia, seminoma or dysgerminoma germ cell tumors, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, childhood glioma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, eosinophilic syndrome, idiopathic eosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, non-small cell lung cancer. In some embodiments, the disease is caused by the kinase activity of c-KIT and / or PDGFRA, and / or its oncogenic forms. In some embodiments, the disease is gastrointestinal stromal tumor (GIST). In some embodiments, the disease is KIT-driven gastrointestinal stromal tumor. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumor. In some embodiments, the disease is lung cancer. In some embodiments, the disease is glioblastoma. In some embodiments, the disease is glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is hypereosinophilic syndrome. In some embodiments, an amorphous form of the compound of formula (I) containing no more than 5% (w / w) of any crystalline form of the compound of formula (I) or no detectable amount of any crystalline form is used in the preparation of a medicament for treating or preventing PDGFR kinase-mediated tumor growth of a tumor. In some embodiments, the tumor growth or tumor progression is caused by overexpression of PDGFRα kinase, oncogenic PDGFRα missense mutations, oncogenic PDGFRα deletion mutations, oncogenic PDGFRα gene rearrangements resulting in PDGFRα fusion proteins, intragenic in-frame deletions of PDGFRα, and / or oncogenic PDGFRα gene amplifications.In some embodiments, an amorphous form of the compound of formula (I) containing no more than 5% (w / w) of any crystalline form of the compound of formula (I) or no detectable amount of any crystalline form is used in the preparation of a medicament for the treatment of a disease, wherein the disease is PDGFRA-driven gastrointestinal stromal tumor, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, gastrointestinal stromal tumor, malignant peripheral nerve sheath sarcoma, intimal sarcoma, eosinophilic syndrome, idiopathic eosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, or lymphoblastic T-cell lymphoma. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumor (GIST). In some embodiments, the disease is lung cancer. In some embodiments, the disease is glioblastoma. In some embodiments, the disease is glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is hypereosinophilic syndrome.

[0183]

[0184] Thus, pharmaceutical compositions and pharmaceutical compositions comprising the amorphous form of the compound of formula (I) described herein may be useful for treating certain disorders in patients in need thereof. In some embodiments, such diseases are caused by the kinase activity of c-KIT or PDGFRA, and oncogenic forms thereof. In some embodiments, the diseases are gastrointestinal stromal tumors (GIST), KIT-driven gastrointestinal stromal tumors, PDGFRA-driven gastrointestinal stromal tumors, melanomas (e.g., cutaneous melanoma, non-cutaneous melanoma, KIT-driven melanoma or PGDFRA-driven melanoma or PGDFR-driven melanoma), acute myeloid leukemia, seminiferous epithelium. In some embodiments, the disease is a germ cell tumor of dysgerminoma or dysgerminoma, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, childhood glioma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, or non-small cell lung cancer. In some embodiments, the disease is gastrointestinal stromal tumor (GIST). In some embodiments, the disease is a KIT-driven gastrointestinal stromal tumor. In some embodiments, the disease is a PDGFRA-driven gastrointestinal stromal tumor. In some embodiments, the disease is lung cancer. In some embodiments, the disease is a glioblastoma. In some embodiments, the disease is a glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is a hypereosinophilic syndrome.

[0184]

[0185] In some embodiments, the disease is PDGFR kinase-mediated tumor growth of tumors. In some embodiments, the tumor growth or tumor progression is caused by overexpression of PDGFRα kinase, oncogenic PDGFRα missense mutations, oncogenic PDGFRα deletion mutations, oncogenic PDGFRα gene rearrangements that generate PDGFRα fusion proteins, PDGFRα intragenic in-frame deletions, and / or oncogenic PDGFRα gene amplifications. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumors, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric glioma, astrocytoma, sarcoma, gastrointestinal stromal tumors, malignant peripheral nerve sheath sarcoma, intimal sarcoma, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, or lymphoblastic T-cell lymphoma. In some embodiments, the disease is PDGFRA-driven gastrointestinal stromal tumor (GIST). In some embodiments, the disease is lung cancer. In some embodiments, the disease is glioblastoma. In some embodiments, the disease is glioma. In some embodiments, the disease is malignant peripheral nerve sheath sarcoma. In some embodiments, the disease is hypereosinophilic syndrome.

[0185]

[0186] The pharmaceutical compositions described herein may be administered to patients (animals and humans) in need of such treatment in dosages that will provide optimal pharmaceutical efficacy. It will be understood that the dosage required for use in any particular application will vary from patient to patient, depending not only on the particular compound or composition selected, but also on the route of administration, the nature of the condition being treated, the age and condition of the patient, any concomitant medications or special diets followed by the patient, and other factors that one skilled in the art would recognize, and that the appropriate dosage will ultimately be left to the discretion of the attending physician.

[0186]

[0187] Treatment can continue for as long or as short as desired. The composition may be administered, for example, on a regimen of 1 to 4 times a day or more. A suitable treatment period can be, for example, at least about 1 week, at least about 2 weeks, at least about 1 month, at least about 6 months, at least about 1 year, or indefinitely. The treatment period can be terminated when the desired results are achieved.

[0187] Combination therapy

[0188] The present disclosure describes combination therapy involving the administration of an amorphous form of the compound of formula (I), or a composition comprising an amorphous form compound of formula (I), and one or more therapeutic agents. The combination therapy described herein can be used by itself or in further combination with one or more additional therapeutic agents (e.g., one or more additional therapeutic agents described below). For example, the compound of formula (I), or a composition comprising an amorphous form compound of formula (I), can be administered with a cancer targeting agent, a cancer targeting biologic, an immune checkpoint inhibitor, or a chemotherapeutic agent. The therapeutic agent can be administered together with another therapeutic agent described herein in combination therapy, or sequentially with the therapeutic agent.

[0188]

[0189] Combination therapy can be achieved by administering two or more therapeutic agents, Each of is formulated and administered separately. Alternatively, combination therapy can be achieved by administering two or more therapeutic agents in a single formulation.

[0189]

[0190] Other combinations are also included in combination therapy. Two or more drugs in combination therapy can be administered at the same time, but it is not necessary. For example, the administration of a first drug (or combination of drugs) can precede the administration of a second drug (or combination of drugs) by minutes, hours, days, or weeks. Thus, two or more drugs can be administered within minutes of each other, or within 1, 2, 3, 6, 9, 12, 15, 18, or 24 hours of each other, or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14 days of each other, or within 2, 3, 4, 5, 6, 7, 8, 9 weeks or more of each other. In some cases, even longer intervals are possible. In many cases, it is desirable, but not necessary, that two or more drugs used in combination therapy are present in the patient's body at the same time.

[0190]

[0191] Combination therapy can also include more than one administration of one or more of the agents used in the combination with the component agents in a different order, for example, when agent X and agent Y are used in combination, they can be administered one or more times sequentially in any combination, for example, in the order XYX, XXY, YXY, YYX, XXYY, etc.

[0191]

[0192] In some embodiments, additional therapeutic agents that may be administered in accordance with the present disclosure include cytotoxic agents, cisplatin, doxorubicin, etoposide, irinotecan, topotecan, paclitaxel, docetaxel, epothilone, tamoxifen, 5-fluorouracil, methotrexate, temozolomide, cyclophosphamide, lonafarib, tipifarnib, 4-((5-((4-(3-chlorophenyl)-3-oxopiperazin-1-yl)methyl)-1H-imidazol-1-yl)methyl)benzonitrile hydrochloride, (R)-1-((1H-imidazol-5-yl)methyl)-3-benzyl-4-(thiophen-2-ylsulfonyl)-2,3,4,5-trifluoroethylene, 1,2-difluoropropanediol ...5-Tetrahydro-1H-benzodiazepine-7-carbonitrile, cetuximab, imatinib, interferon alpha-2b, pegylated interferon alpha-2b, aromatase combination drugs, gemcitabine, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, floxuridine, cytarabine, 6- Mercaptopurine, 6-thioguanine, fludarabine phosphate, leucovorin, oxaliplatin, pentostatin, vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, epirubicin, idarubicin, mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, teniposide 17α-ethynyl estradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, dodecyl propionate Lomostanolone, testolactone, megestrol acetate, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, 17α-hydroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesterone acetate, leuprolide acetate, flutamide, toremifene citrate, goserelin acetate, carboplatin, hydroxyurea, amsacrine, procarbazine, mitotane, mitoxantrone, levamisole, vinorelbine, anas These include, but are not limited to, trazol, letrozole, capecitabine, raloxifene, droloxafine, hexamethylmelamine, bevacizumab, trastuzumab, tositumomab, bortezomib, ibritumomab tiuxetan, arsenic trioxide, porfimer sodium, cetuximab, thiotepa, altretamine, fulvestrant, exemestane, rituximab, alemtuzumab, dexamethasone, bicalutamide, chlorambucil, and valrubicin.

[0192]

[0193] In some embodiments, additional therapeutic agents that can be administered include AKT inhibitors, alkylating agents, all-trans-retinoic acid, antiandrogens, azacytidine, BCL2 inhibitors, BCL-XL inhibitors, BCR-ABL inhibitors, BTK inhibitors, BTK / LCK / LYN inhibitors, CDK1 / 2 / 4 / 6 / 7 / 9 inhibitors, CDK4 / 6 inhibitors, CDK9 inhibitors, CBP / p300 inhibitors, EGFR inhibitors, endothelin receptor blockers, RAF inhibitors, MEK (mitogen-activated protein kinase) inhibitors, ERK inhibitors, farnesyltransferase inhibitors, FLT3 inhibitors, agents, glucocorticoid receptor agonists, HDM2 inhibitors, histone deacetylase inhibitors, IKKβ inhibitors, immunomodulatory drugs (IMiDs), ingenol, Itk inhibitors, JAK1 / JAK2 / JAK3 / TYK2 inhibitors, MTOR inhibitors, PI3 kinase inhibitors, dual PI3 kinase / MTOR inhibitors, proteasome inhibitors, protein kinase C agonists, SUV39H1 inhibitors, TRAIL, VEGFR2 inhibitors, Wnt / β-catenin signaling inhibitors, decitabine, and anti-CD20 monoclonal antibodies.

[0193]

[0194] In certain embodiments, the additional therapeutic agent is a CTLA4 inhibitor (such as, but not limited to, ipilimumab and tremelimumab), a PD1 inhibitor (such as, but not limited to, pembrolizumab and nivolumab), a PDL1 inhibitor (such as, but not limited to, atezolizumab (formerly MPDL3280A), durvalumab (formerly MEDI4736), avelumab, PDR001), 4 1BB or 4 1BB ligand inhibitors (such as but not limited to urelumab and PF-05082566), OX40 ligand agonists (such as but not limited to MEDI6469), GITR agents (such as but not limited to TRX518), CD27 inhibitors (such as but not limited to varlilumab), TNFRSF25 or TL1A inhibitors, CD40 agonists (such as but not limited to CP-870893), HVEM or LIGHT or LTA or BTLA or CD160 inhibitors, LAG3 inhibitors (such as but not limited to BMS-986016), TIM3 inhibitors, Siglecs inhibitors, ICOS or ICOS ligand agonists, B7 H3 inhibitors (such as but not limited to MGA271), B7 H4 inhibitors, VISTA inhibitors, HHLA2 or TMIGD2 inhibitors, butyrophilin inhibitors (including BTNL2 inhibitors), CD244 or CD48 inhibitors, inhibitors of TIGIT and PVR family members, KIR inhibitors (such as, but not limited to, lirilumab), inhibitors of ILT and LIR, NKG2D and NKG2A inhibitors (such as, but not limited to, IPH2201), inhibitors of MICA and MICB, CD244 inhibitors, CSF1R inhibitors (such as, but not limited to, , ctuzumab, cabirarizumab, pexidartinib, ARRY382, BLZ945, etc., IDO inhibitors (such as but not limited to INCB024360), thalidomide, lenalidomide, TGFβ inhibitors (such as but not limited to galunisertib), adenosine or CD39 or CD73 inhibitors, CXCR4 or CXCL12 inhibitors (urocupulumab and (3S,6S,9S,12R,17R,20S,23S,26S,29S,34aS)-N-((S)-1-amino-5-guanidino-1-oxopentan-2-yl)-26,29-bis(4-aminobutyl)-17-((S)-2-((S)-2-((S)-2-(4-fluorobenzamido)-5-guanidinopentanamido)-5-guanidinopentanamido)-3-(naphthalen-2-yl)propanamido)-6-(3-guanidinopropyl)-3,20-bis(4-hydroxybenzyl)-1,4,7,10,18,21,24,27,30-nonaoxo-9,23-bis(3- ureidopropyl)triacontahydro-1H,16H-pyrrole[2,1-p][1,2]dithia[5,8,11,14,17,20,23,26,29]nonaazacyclodotriacontin-12-carboxamide BKT140), phosphatidylserine inhibitors (such as, but not limited to, bavituximab), SIRPA or CD47 inhibitors (such as, but not limited to, CC-90002), VEGF inhibitors (such as, but not limited to, bevacizumab), and and neuropilin inhibitors (such as, but not limited to, MNRP1685A).

[0194]

[0195] In some embodiments, the additional therapeutic agent is a chemotherapeutic agent selected from the group consisting of chemotherapeutic agents including, but not limited to, antitubulin agents (paclitaxel, paclitaxel protein-bound particles for injectable suspension (nab-paclitaxel, eribulin, docetaxel, ixabepilone, vincristine)), vinorelbine, DNA alkylating agents (including cisplatin, carboplatin, oxaliplatin, cyclophosphamide, ifosfamide, temozolomide), DNA intercalating agents (including doxorubicin, pegylated liposomal doxorubicin, daunorubicin, idarubicin, and epirubicin), 5-fluorouracil, capecitabine, cytarabine, decitabine, 5-azacitadine, gemcitabine, and methotrexate.

[0195]

[0196] In some embodiments, the additional therapeutic agent is selected from the group consisting of paclitaxel, paclitaxel protein-bound particles for injectable suspension, eribulin, docetaxel, ixabepilone, vincristine, vinorelbine, cisplatin, carboplatin, oxaliplatin, cyclophosphamide, ifosfamide, temozolomide, doxorubicin, pegylated liposomal doxorubicin, daunorubicin, idarubicin, epirubicin, 5-fluorouracil, capecitabine, cytarabine, decitabine, 5-azacitadine, gemcitabine, methotrexate, erlotinib, gefitinib, lapatinib, everolimus, temsirolimus, LY2835219, LEE011, PD 0332991, crizotinib, cabozantinib, sunitinib, pazopanib, sorafenib, regorafenib, axitinib, dasatinib, imatinib, nilotinib, vemurafenib, dabrafenib, trametinib, idelasib, quizartinib, tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, abiraterone acetate, enzalutamide, nilutamide, bicalutamide, flutamide, cyproterone acetate, prednisone, dexamethasone, irinotecan, camptothecin, topotecan, etoposide, etoposide phosphate, mitoxantrone, vorinostat, romidepsin, panobinostat, valproic acid, belinostat, DZNep Selected from the group consisting of 5-aza-2'-deoxycytidine, bortezomib, carfilzomib, thalidomide, lenalidomide, pomalidomide, trastuzumab, pertuzumab, cetuximab, panitumumab, ipilimumab, ravlolizumab, nivolumab, MPDL3280A, bevacizumab, aflibercept, brentuximab vedotin, ado-trastuzumab emtansine, radiation therapy, and sipuleucel-T.

[0196]

[0197] In some embodiments, the additional therapeutic agent is a kinase inhibitor selected from the group consisting of erlotinib, gefitinib, lapatanib, everolimus, temsirolimus, LY2835219, LEE011, PD 0332991, crizotinib, cabozantinib, sunitinib, pazopanib, sorafenib, regorafenib, axitinib, dasatinib, imatinib, nilotinib, vemurafenib, dabrafenib, trametinib, idelalisib, and quizartinib.

[0197]

[0198] In some embodiments, the additional therapeutic agent is an anti-PD1 therapeutic agent.The examples of the anti-PD1 therapeutic agent that can be administered in combination with the compound of formula (I) or its pharmaceutically acceptable salt or the composition comprising the compound of formula (I) or its pharmaceutically acceptable salt include but are not limited to nivolumab, pidilizumab, cemiplimab, tisulezumab, AMP-224, AMP-514 and pembrolizumab.

[0198]

[0199] In some embodiments, the additional therapeutic agent is an anti-PD-L1 therapeutic, including atezolizumab, durvalumab, BMS-936559, and avelumab; an anti-TIM3 therapeutic, including TSR-022 and MBG453; leratolimab, LAG525, and TS The additional therapeutic agent is selected from the group consisting of immunomodulatory agents, including, but not limited to, anti-LAG3 therapeutic agents, including R-033, CD40 agonist therapeutic agents, including SGN-40, CP-870,893, and RO7009789, anti-CD47 therapeutic agents, including Hu5F9-G4, anti-CD20 therapeutic agents, anti-CD38 therapeutic agents, or other immunomodulatory therapeutic agents, including thalidomide, lenalidomide, pomalidomide, prednisone, and dexamethasone. In some embodiments, the additional therapeutic agent is avelumab.

[0199]

[0200] In some embodiments, the additional therapeutic agent is an anti-tubulin agent (e.g., paclitaxel, paclitaxel protein-bound particles for injectable suspension, eribulin, abraxane, docetaxel, ixabepilone, taxitereme, vincristine, or vinorelbine), an LHRH antagonist (including but not limited to leuprolide, goserelin, triptorelin, or histrelin), an anti-angiogenic agent (including but not limited to abiraterone, flutamide, bicalutamide, nilutamide, cyproterone acetate, enzalutamide, and apalutamide), an anti-estrogen agent (tamoxifen, fulvestra), The chemotherapeutic agent is selected from the group consisting of: cisplatin, anastrozole, letrozole, and exemestane), DNA alkylating agents (including cisplatin, carboplatin, oxaliplatin, cyclophosphamide, ifosfamide, and temozolomide), DNA intercalating agents (including doxorubicin, pegylated liposomal doxorubicin, daunorubicin, idarubicin, and epirubicin), 5-fluorouracil, capecitabine, cytarabine, decitabine, 5-azacytidine, gemcitabine methotrexate, bortezomib, and carfilzomib.

[0200]

[0201] In some embodiments, the additional therapeutic agent is a targeted therapeutic agent (kinase inhibitors erlotinib, gefitinib, lapatanib, everolimus, temsirolimus, abemaciclib, LEE011, palbociclib, crizotinib, cabozantinib, sunitinib, pazopanib, sorafenib, regorafenib, axitinib, dasatinib, imatinib, nilotinib, vemurafenib, dabrafenib, trametinib, cobimetinib, binimetinib, idelalisib, quizartinib, avapritinib, BLU-667, BL U-263, Loxo292, latrorectinib, and quizartinib), antiestrogens (including but not limited to tamoxifen, fulvestrant, anastrozole, letrozole, and exemestane), antiandrogens (including but not limited to abiraterone acetate, enzalutamide, nilutamide, bicalutamide, flutamide, cyproterone acetate), steroids (including but not limited to prednisone and dexamethasone), PARP inhibitors (including but not limited to neraparib, oraparin, valproate ... paribu, and rucaparib), topoisomerase I inhibitors (including but not limited to irinotecan, camptothecin, and topotecan), topoisomerase II inhibitors (including but not limited to etoposide, etoposide phosphate, and mitoxantrone), histone deacetylase (HDAC) inhibitors (including but not limited to vorinostat, romidepsin, panobinostat, valproic acid, and belinostat), DNA methylation inhibitors (DZNep and and 5-aza-2'-deoxycytidine), proteasome inhibitors (including but not limited to bortezomib and carfilzomib), biologics (including but not limited to thalidomide, lenalidomide, pomalidomide, trastuzumab, ado-trastuzumab, pertuzumab, cetuximab, panitumumab, ipilimumab, tremelimumab), vaccines (including but not limited to sipuleucel-T), and radiation therapy.

[0201]

[0202] In some embodiments, the additional therapeutic agent is selected from the group consisting of inhibitors of TIE2 immune kinase, including revastinib or ARRY-614.

[0202]

[0203] In some embodiments, the additional therapeutic agent is revastinib or ARRY-614. and anti-PD1 therapeutic agents.

[0203]

[0204] In some embodiments, the additional therapeutic agent is selected from the group consisting of angiogenesis inhibitors, including AMG386, bevacizumab, and aflibercept, and antibody-drug-conjugates (ADCs), including brentuximab vedotin, trastuzumab emtansine, and ADCs comprising a payload, such as a derivative of camptothecin, a pyrrolobenzodiazepine dimer (PBD), an indolinobenzodiazepine dimer (IGN), DM1, DM4, MMAE, or MMAF.

[0204]

[0205] In some embodiments, the additional therapeutic agent is selected from luteinizing hormone releasing hormone (LHRH) analogs, including goserelin and leuprolide.

[0205]

[0206] In some embodiments, the additional therapeutic agent is everolimus, trabectedin, abraxane, TLK 286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, pemetrexed, erlotinib, dasatanib, nilotinib, decatanib, panitumumab, amrubicin, oregovomab, Lep-etu, nolatrexed, azd2171, butabulin, atumtunab, zanolimumab, edotecarin, tetrandrine, rubitecan, tesmifene, oblimersen, ticilimumab, ipilimumab, gossypol, Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC 8490, Cilengitide, Jaimatecan, IL13-PE38QQR, INO 1001, IPdR1 KRX-0402, Lucanton, LY 317615, Neurajiab, Vitespam, Rta 744, Sdx 102, Talampanel, Atrasentan, Xr 311, romidepsin, ADS-100380, sunitinib, 5-fluorouracil, vorinostat, etoposide, gemcitabine, doxorubicin, irinotecan, liposomal doxorubicin, 5'-deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709, seliciclib; PD0325901, AZD-6244, capecitabine, L-glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)- ethyl]benzoyl]-, disodium salt, heptahydrate, camptothecin, PEG-labeled irinotecan, tamoxifen, toremifene citrate, anastrozole, exemestane, letrozole, DES (diethylstilbestrol), estradiol, estrogen, conjugated estrogen, bevacizumab, IMC-1C11, CHIR-258; 3-[5-(methylsulfonylpiperazinemethyl)-indolyl]-quinolone, vatalanib, AG-013736, AVE-0005, acetate salt of [D-Ser(Bu t)6, Azgly 10] (pyro-Glu-His-Trp-Ser-Tyr-D-Ser(Bu t)-Leu-Arg-Pro-Azgly-NH2 acetate [C.59 H 84 N 18 Oi4-(C2H4O2) x (wherein x=1-2.4)], goserelin acetate, leuprolide acetate, triptorelin pamoate, medroxyprogesterone acetate, hydroxyprogesterone caproate, megestrol acetate, raloxifene, bicalutamide, furutanide, nilutamide, megestrol acetate, CP-724714; TAK-165, HKI-272, erlotinib, lapatanib, canertinib, ABX-EGF antibody, arbiter , EKB-569, PKI-166, GW-572016, ionafarnib, BMS-214662, tipifarnib; amifostine, NVP-LAQ824, suberoylanilide hydroxamic acid, valproic acid, trichostatin A, FK-228, SU11248, sorafenib, KRN951, aminoglutethimide, amsacrine, anagrelide, L-asparaginase, abolished Mycobacterium bovis (BCG) ) Vaccines, bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxymesterone, flutamide, gemcitabine, Gleevec, hydroxyurea, idarubicin, ifosfamide, imatinib, leuprolide, levamisole, lomustine, mechlorethamine, melphalan, 6-mercapto Toprine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, octreotide, oxaliplatin, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, teniposide, testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine, 13-cis-retinoic acid, phenylalanine mustard, uracil mustard, estramustine, altretamine, floxuridine, 5-deoxyuridine, cytochrome P450, cytochrome P450 Tosine arabinoside, 6-mecaptopurine, deoxycoformycin, calcitriol, valrubicin, mithramycin, vinblastine, vinorelbine, topotecan, razoxine, marimastat, COL-3, neovastat, BMS-275291, squalamine, endostatin, SU5416, SU6668, EMD121974, interleukin-12, IM862, angiostatin, vitaxin, droloxifene, idoxifene, spironolactone, finasteride, cimitidine, trastuzumab, denileukin diftitoc s, gefitinib, bortezimib, irinotecan, topotecan, doxorubicin, docetaxel, vinorelbine, bevacizumab (monoclonal antibody) and erbitux, cremophor-free paclitaxel, epithilone B, BMS-247550, BMS-310705, droloxifene, 4-hydroxytamoxifen, pipendoxifene, ERA-923, arzoxifene, fulvestrant, acolbifene, lasofoxifene, idoxifene, TSE-424, HMR-3339, ZK186619, PTK787 / ZK222584, VX-745, PD 184352, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001, ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646, wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zoledronate, prednisone, Cetuximab, granulocyte-macrophage colony-stimulating factor, histrelin, pegylated interferon alpha-2a, interferon alpha-2a, pegylated interferon alpha-2b, interferon alpha-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane, alemtuzumab, all-trans retinoic acid, ketoconazole, interleukin-2 , megestrol, immunoglobulin, nitrogen mustard, methylprednisolone, ibritumomab tiuxetan, androgens, decitabine, hexamethylmelamine, bexarotene, tositumomab, arsenic trioxide, cortisone, editronate, mitotane, cyclosporine, liposomal daunorubicin, edwina-asparaginase, strontium 89, casopitant, netupitant, NK1 receptor blockers, palonosetron, aprepitant, dif and mixtures thereof.

[0206]

[0207] In some embodiments, the additional therapeutic agent is an HSP90 inhibitor (e.g., AT13387). In some embodiments, the additional therapeutic agent is cyclophosphamide. In some embodiments, the additional therapeutic agent is an AKT inhibitor (e.g., perifosine). In some embodiments, the additional therapeutic agent is a BCR-ABL inhibitor (e.g., nilotinib). In some embodiments, the additional therapeutic agent is an mTOR inhibitor (e.g., RAD001). In some embodiments, the additional therapeutic agent is an FGFR inhibitor (e.g., erdafitinib, KO947, or BGJ398). In some embodiments, the additional therapeutic agent is an anti-PDL1 therapeutic agent. In some embodiments, the additional therapeutic agent is a Bcl2 inhibitor (e.g., venetoclax). In some embodiments, the additional therapeutic agent is an autophagy inhibitor (e.g., hydroxychloroquine). In some embodiments, the additional therapeutic agent is a MET inhibitor. EXAMPLES

[0207]

[0208] The present disclosure is not intended to be limited in scope by the specific embodiments disclosed in the examples, which are intended as illustrations of some aspects of the disclosure, and any embodiments that are functionally equivalent are within the scope of the present disclosure. Indeed, various modifications in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the scope of the appended claims.

[0208]

[0209] In the examples below, the following abbreviations are used: "HPMCAS-HG" refers to hydroxymethylpropyl acetate succinate cellulose (high pH solubility, granules), "SDD" refers to spray dried dispersion, and "PVP-XL" refers to cross-linked polyvinylpyrrolidone. In the examples provided below, "Compound 1" refers to a compound of formula (I) as described herein. "Impurity A" and "Compound 2" each refer to a compound of formula (II) as described herein. "Compound 3" refers to a compound of formula (III) as described herein.

[0209]

[0210] As used in Example 1 below, "w / w suspension percentage" is the percentage of a component of the suspension used to prepare the spray-dried dispersion based on the amount of Compound 1 in the suspension, as a weight percentage. EXAMPLES

[0210] Example 1 Preparation of a spray-dried dispersion containing Compound 1 and HPMCAS-HG.

[0211]

[0211] Preparation of the Suspension. HPMCAS-HG is added to the purified water and acetone solution and mixed to ensure dissolution of the polymer. Crystalline Compound 1 is added to the solution and the suspension is mixed at a temperature of 15-25°C. Mixing is continued for the remainder of the spray drying process.

[0212]

[0212] Preparation and use of start / stop solvent. Mix purified water and acetone. The start and stop solvents are sprayed at the beginning and end of the spray drying cycle.

[0213] Spray drying. The suspension is passed through an in-line heat exchanger (flow rate 38-51 kg / hr) to heat the suspension to a temperature range of 112-124°C to dissolve the suspended particles prior to spray drying. The solution is then spray dried in a pharmaceutical spray dryer (PSD-2 or equivalent) equipped with a capillary nozzle assisted by nitrogen sheath gas pressure of 65-85 psig using 400-500 kg / hr of bulk drying gas, a chamber outlet temperature of 50-70°C, and a condenser temperature of -10°C.

[0214] Secondary Drying: The partially wet spray-dried intermediate resulting from the above preparation is dried to provide an SDD comprising Compound 1 and HPMCAS-HG using an agitated vacuum dryer at a temperature range of 40-50° C. and a chamber pressure of 40-50 mbar. EXAMPLES

[0215] Example 2 Preparation of a spray-dried dispersion containing Compound 1 and HPMCAS-HG.

[0216]

[0215] Preparation of solutions. Crystalline Compound 1 is added to a purified water and THF solution and mixed to ensure the compound is dissolved. HPMCAS-HG is added to the solution and mixed at ambient temperature until the polymer is dissolved.

[0217]

[0216] Preparation and use of start / stop solvent. Mix purified water and THF. The start and stop solvents are sprayed at the beginning and end of the spray drying cycle.

[0218] Spray Drying The solution is then spray dried in a pharmaceutical spray dryer using a spray rate of 175-205 g / min, a bulk drying gas flow rate of 1550-2150 g / min, and a chamber outlet temperature of 40-50°C.

[0219] Secondary Drying: The partially wet spray-dried intermediate resulting from the above preparation is dried using a tray dryer at a temperature range of 15-45° C. to provide an SDD comprising Compound 1 and HPMCAS-HG. EXAMPLES

[0220] Example 3 Purity by HPLC for solid dispersions containing amorphous compound of formula (I).

[0221]

[0219] Table 1 shows the purity, as determined by HPLC, for the solid dispersions, each containing an amorphous form of the compound of Formula (I). Each lot (Lot 1, Lot 2, Lot 3, and Lot 4) was prepared according to the process outlined in Example 1. [Table 1] EXAMPLES

[0222] Example 4 Stability study of the amorphous form of the compound of formula (I) in solid dispersion.

[0223]

[0220] Studies on the amorphous form of the compound of formula (I) in solid dispersions are described. Tables 2(a)-(c) show the conditions (temperature and relative humidity) applied, the glass transition temperature (T gThese studies are described for samples (Lot 5, Lot 6, and Lot 7) prepared according to the process of Example 1 at the specified time points, including evaluation of crystallinity by XPRD, and determination of the amount of impurity A in the samples. This study shows that solid dispersions comprising amorphous compound of formula (I) are surprisingly highly stable and do not exhibit polymorphic conversion to a crystalline form under harsh conditions of high relative humidity and high temperature. [Table 2a] [Table 2b] [Table 2c]

[0224]

[0221] In one aspect, the amorphous compound of formula (I) is characterized by an X-ray diffraction pattern substantially as shown in Figure 1. Described herein are amorphous compounds of formula (I). The amorphous form may be characterized by an amorphous "halo" PXRD pattern, an X-ray powder diffraction pattern substantially as shown in Figure 1, and combinations of this data. The amorphous compound of formula (I) may be prepared by the process of dissolving the compound of formula (I), spray drying the solution of the compound, and drying the spray dried compound. EXAMPLES

[0225] Example 5 Solubility Study of Solid Dispersions Containing Amorphous Form of Compound of Formula (I)

[0226] The solubility of the amorphous Compound 1 (25%) / HPMCAS-HG solid dispersion prepared in Example 1 at selected pH values ​​was evaluated. In particular, Table 3 shows the kinetic solubility of crystalline Compound 1 and the solid dispersion of amorphous Compound 1 (25%) / HPMCAS-HG at selected pH values. Table 3 shows the significantly enhanced solubility of the solid dispersion compared to the crystalline form of Compound 1. [Table 3] EXAMPLES

[0227] Example 6 Pharmacokinetic study of Compound 1 spray-dried dispersions.

[0228] A study was conducted in rats to compare the pharmacokinetics of crystalline Compound 1 and solid dispersion of amorphous Compound 1 (25%) prepared in Example 1. The dose for both studies was 10 mg / kg (based on Compound 1). Rats were administered crystalline Compound 1 as an oral suspension in a solvent of 20% Captisol / 0.4% HPMC at pH 2. Rats were administered amorphous Compound 1 as an oral suspension with a solvent of 0.5% Methocel. The results of the study are shown in Table 4 and show the unexpected enhanced pharmacokinetic profile of the solid dispersion. [Table 4] EXAMPLES

[0229] Example 7. Tablet preparation.

[0230]

[0224] The spray-dried dispersion of Compound 1 and HPMCAS-HG described in Example 1 is first mixed with all intragranular ingredients except the lubricant magnesium stearate in a suitable diffusion mixer (bin blender or equivalent). The initial preblend is degassed and re-blended (before lubricant blending) through a screening mill (such as a co-mill, or equivalent) prior to the addition of magnesium stearate and blend (after lubricant blending). The final blend is compressed into tablets using a suitable power-assisted rotary tablet press. Exemplary tablet compositions containing 25 mg Compound 1 or 50 mg Compound 1 are provided below in Tables 5 and 6, respectively. In Table 5, the spray-dried intermediates of tablets 1, 2, and 3, respectively, were prepared by the process of Example 2. In Table 6, the spray-dried intermediates of tablet 4 were prepared by the process of Example 2. The intermediate was prepared by the process of Example 2 and the spray-dried intermediate of tablet 5 was prepared by the process of Example 1. [Table 5] [Table 6] EXAMPLES

[0231] Example 8 Tablet dissolution test

[0232]

[0225] Tablets manufactured using the process and formulation described in Example 7 were subjected to dissolution testing using the dissolution apparatus parameters set forth in Table 7, and the HPLC apparatus parameters for analysis of dissolution samples in Table 8. [Table 8] [Table 9]

[0233]

[0226] Study of the test properties of exemplary 50 mg Compound 1 tablets (DOE1, DOE2, DOE3, and DOE4), including the percent dissolution released as a function of time using the dissolution methods described above. Figure 2 summarizes the dissolution profile of each tablet studied in Table 10. [Table 10]

[0234] Additionally, Table 11 shows the dissolution and other attributes of three exemplary batches of 50 mg Compound 1 tablets prepared using the process described in Example 7 (Tablet 5). A spray-dried intermediate was prepared according to the procedure in Example 1. The dissolution % release was measured using the dissolution test method described above. [Table 11] EXAMPLES

[0235] Example 9 Preparation of the compound of formula (III) reference standard.

[0236] 3-(5-amino-2-bromo-4-fluorophenyl)-1-ethyl-7-(methylamino)-1,6-naphthyridin-2(1H)-one (40 g), phenyl isocyanate (30 g, 2.7 eq.), pyridine (3 eq.) and methanesulfonic acid (1 eq.) were combined in a solvent consisting of 1-methyl-2-pyrrolidinone (10 vol.) and tetrahydrofuran (5 vol.). The mixture was stirred at 50° C. for 7 days with occasional addition of an additional 0.1-0.2 eq. of phenyl isocyanate (0.1-0.2 eq.) to give crude 1-(3-(2-bromo-4-fluoro-5-(3-phenylureido)phenyl)-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-7-yl)-1-methyl-3-phenylurea wet solid. The crude wet solid was crystallized from 1-methyl-2-pyrrolidinone (4 volumes) and methanol (8 volumes) to give 57 g of 1-(3-(2-bromo-4-fluoro-5-(3-phenylureido)phenyl)-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-7-yl)-1-methyl-3-phenylurea. MS m / z: 629 (M+1). 1 H NMR (400MHz, DMSO-d6): δ 11.44 (s, 1H), 9.12 (s, 1H), 8.84 (s, 1H), 8.74 (s, 1H), 8.29 and 8.27 (d, 1H), 8.02 (s, 1H), 7.72 and 7.70 (d, 1H), 7.59 and 7.57 (d, 2H), 7.45 and 7.43 (d, 2H), 7.34-7.26 (m, 4 H),7.24(s,1 H),7.06-6.97(m,2 H),4.35-4.28(m,2 H),3.53(s,3 H),1.27-1.23(t,3 H).

[0237] Equivalent

[0229] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments specifically described herein. Such equivalents are intended to be encompassed by the scope of the following claims.

Claims

1. A pharma- ceutically acceptable composition for oral administration, comprising: (i) A solid dispersion comprising: Formula (I): 【Chemistry 1】 and an amorphous form of the compound represented by and a pharma- ceutically acceptable polymer; and (ii) one or more pharma- ceutically acceptable excipients.

2. 2. The pharma- ceutically acceptable composition of claim 1, wherein the solid dispersion has no more than about 5% w / w of the compound in any crystalline form.

3. 3. The pharma- ceutically acceptable composition of claim 1 or 2, wherein the solid dispersion is substantially free of detectable amounts of any crystalline form of the compound.

4. 4. The pharma- ceutically acceptable composition of any one of claims 1 to 3, wherein said amorphous form has an X-ray powder diffraction pattern substantially as shown in Figure 1.

5. 5. The pharma- ceutically acceptable composition of any one of claims 1-4, wherein the composition contains no more than about 5% (w / w) of any crystalline form of the compound in the aggregate when exposed to 60% relative humidity at 25° C. for 1 month, 3 months, or 6 months.

6. 5. The pharma- ceutically acceptable composition of any one of claims 1-4, wherein the composition contains no more than about 5% (w / w) of any crystalline form of the compound in the aggregate when exposed to 75% relative humidity at 40° C. for 1 month, 3 months, or 6 months.

7. 7. The pharma- ceutically acceptable composition of any one of claims 1 to 6, comprising about 10% to about 30% by weight of said compound, based on the total weight of said solid dispersion.

8. 8. The pharma- ceutically acceptable composition of any one of claims 1 to 7, comprising about 20% to about 30% by weight of said compound, based on the total weight of said solid dispersion.

9. 9. The pharma- ceutically acceptable composition of any one of claims 1 to 8, comprising about 25% by weight of said compound, based on the total weight of said solid dispersion.

10. Pharmaceutically acceptable polymers include polyvinylpyrrolidone, polyethylene oxide, polyethylene glycol, poly(vinylpyrrolidone-co-vinyl acetate), polyoxyethylene-polyoxypropylene block copolymers, graft copolymers (composed of polyethylene glycol, polyvinylcaprolactam and polyvinyl acetate), polymethacrylates, polyoxyethylene alkyl ethers, polyoxyethylene castor oil, polycaprolactam, polyoxyethylene propylene glycol ... cellulose, polylactic acid, polyglycolic acid, poly(lactic-glycolic) acid, lipids, cellulose, pullulan, dextran, maltodextrin, hyaluronic acid, polysialic acid, chondroitin sulfate, heparin, fucoidan, polysulfate pentosan, spirulan, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose propionate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, methylcellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, carboxymethylethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate phthalate, hydroxypropyl methylcellulose propionate phthalate, hydroxypropyl methylcellulose acetate trimellitate, hydroxypropyl methylcellulose propionate trimellitate, cellulose acetate succinate, methylcellulose acetate succinate cellulose, dextran, dextran acetate, dextran tropionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran tropionate succinate, dextran acetate propionate succinate, poly(methacrylic acid-co-methyl methacrylate) 1:1, poly(methacrylic acid-co-methyl methacrylate) 1:2, poly(methacrylic acid-co-ethyl acrylate) 1:1, hydroxyethyl cellulose, methyl cellulose and 10. The pharma- ceutically acceptable composition of any one of claims 1 to 9, wherein the polysaccharide is selected from the group consisting of hydroxypropylcellulose, polymethacrylic acid-ethyl acrylate, polymethacrylic acid-methyl methacrylate, polymethyl methacrylate-ethyl acrylate, polytrimethylammonioethyl methacrylate, methyl methacrylate-ethyl acrylate, and poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate), and mixtures thereof.

11. Pharmaceutically acceptable polymers include polyvinylpyrrolidone, polyethylene oxide, polyethylene glycol, poly(vinylpyrrolidone-co-vinyl acetate), polyoxyethylene-polyoxypropylene block copolymers, graft copolymers (composed of polyethylene glycol, polyvinylcaprolactam and polyvinyl acetate), polymethacrylates, polyoxyethylene alkyl ethers, polyoxyethylene castor oil, polycaprolactam, polylactic acid, polyglycolic acid, poly(lactic-glycolic) acid, lipids, cellulose, pullulan, dextran, maltodextrin, hyaluronic acid, polysialic acid, chondroitin sulfate, heparin, fucoidan, pentosan polysulfate, spirulan, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose propionate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, methylcellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate 11. The pharma- ceutically acceptable composition of any one of claims 1 to 10, wherein the cellulose acetate is selected from the group consisting of cellulose acetate terephthalate, cellulose acetate isophthalate, carboxymethylethylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate phthalate, hydroxypropylmethylcellulose propionate phthalate, hydroxypropylmethylcellulose acetate trimellitate, hydroxypropylmethylcellulose propionate, cellulose acetate succinate, methylcellulose acetate succinate, dextran, dextran acetate, dextran tropionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran tropionate succinate, dextran acetate propionate succinate, poly(methacrylic acid-co-methyl methacrylate) 1:1, poly(methacrylic acid-co-methyl methacrylate) 1:2, poly(methacrylic acid-co-ethyl acrylate) 1:1, and mixtures thereof.

12. A pharma- ceutically acceptable composition according to any one of claims 1 to 11, wherein the pharma- ceutically acceptable polymer is hydroxypropyl methylcellulose acetate succinate.

13. 13. The pharma- ceutically acceptable composition of any one of claims 1 to 12, wherein said compound and said pharma- ceutically acceptable polymer are present in a compound:polymer ratio of about 40:60 to about 10:

90.

14. 14. The pharma- ceutically acceptable composition of any one of claims 1 to 13, wherein said compound and said pharma- ceutically acceptable polymer are present in a compound:polymer ratio of about 30:70 to about 20:

80.

15. 15. The pharma- ceutically acceptable composition of any one of claims 1 to 14, wherein said compound and said pharma- ceutically acceptable polymer are present in a compound:polymer ratio of about 25:

75.

16. 16. The pharma- ceutically acceptable composition of any one of claims 1 to 15, wherein the solid dispersion is a solid spray dried dispersion.

17. 17. The pharma- ceutically acceptable composition of any one of claims 1 to 16, wherein the solid dispersion has a solubility in water of pH 6.5 at 25°C of about 120 µg / mL.

18. 18. The pharma- ceutically acceptable composition of any one of claims 1 to 17, wherein the solid dispersion has a solubility in water at pH 2 at 25°C of about 178 μg / mL.

19. Based on the weight of the compound of formula (I), less than about 10% by weight of the compound of formula (II): 【Chemistry 2】 19. The pharma- ceutically acceptable composition of any one of claims 1 to 18, comprising a compound represented by the formula:

20. Based on the weight of the compound of formula (I), less than about 3% by weight of the compound of formula (II): 【Chemistry 3】 20. The pharma- ceutically acceptable composition of any one of claims 1 to 19, comprising a compound represented by the formula:

21. Based on the weight of the compound of formula (I), less than about 1% by weight of the compound of formula (II): 【Chemistry 4】 21. The pharma- ceutically acceptable composition of any one of claims 1 to 20, comprising a compound represented by the formula:

22. Based on the weight of the compound of formula (I), about 0.1% by weight to about 0.5% by weight of the compound of formula (II): 【Chemistry 5】 22. The pharma- ceutically acceptable composition of any one of claims 1 to 21, comprising a compound represented by the formula:

23. Based on the weight of the compound of formula (I), about 0.01% by weight to about 0.1% by weight of the compound of formula (II): 【Chemistry 6】 23. The pharma- ceutically acceptable composition of any one of claims 1 to 22, comprising a compound represented by the formula:

24. Based on the weight of the compound of formula (I), less than about 10% by weight of the compound of formula (III): 【Chemistry 7】 24. The pharma- ceutically acceptable composition of any one of claims 1 to 23, comprising a compound represented by the formula:

25. Based on the weight of the compound of formula (I), less than about 3% by weight of the compound of formula (III): 【Chemistry 8】 25. The pharma- ceutically acceptable composition of any one of claims 1 to 24, comprising a compound represented by the formula:

26. Based on the weight of the compound of formula (I), less than about 1% by weight of the compound of formula (III): 【Chemistry 9】 26. The pharma- ceutically acceptable composition of any one of claims 1 to 25, comprising a compound represented by the formula:

27. About 0.1% to about 0.5% by weight of the compound of formula (I): 【Chemistry 10】 27. The pharma- ceutically acceptable composition of any one of claims 1 to 26, comprising a compound represented by the formula:

28. About 0.01% to about 0.1% by weight of the compound of formula (I): 【Chemistry 11】 29. The pharma- ceutically acceptable composition of any one of claims 1 to 28, comprising a compound represented by the formula:

29. A compound represented by formula (I) 【Chemistry 12】 and a pharma- ceutically acceptable composition comprising a pharma- ceutically acceptable excipient, wherein greater than about 96% by weight of said compound present in said pharma- ceutically acceptable composition is in said amorphous form.

30. 30. The pharma- ceutically acceptable composition of claim 29, wherein the amorphous form has a characteristic amorphous X-ray powder diffraction halo pattern.

31. 31. The pharma- ceutically acceptable composition according to claim 29 or 30, wherein said amorphous form has an X-ray powder diffraction pattern substantially as shown in Figure 1.

32. 31. The pharma- ceutically acceptable composition of claim 29 or 30, wherein the powder X-ray diffraction spectrum is obtained using Cu Kα radiation.

33. 33. The pharma- ceutically acceptable composition of any one of claims 29 to 32, wherein the amorphous form of the compound has a glass transition temperature of about 125°C.

34. 34. The pharma- ceutically acceptable composition of any one of claims 29 to 33, wherein said composition does not contain a detectable amount of any crystalline form of said compound of formula (I).

35. Formula (I): 【Chemistry 13】 A pharma- ceutical acceptable composition for orally delivering 50 mg of a compound represented by the formula: An intragranular blend, comprising: a solid dispersion having 50 mg of the compound, the compound being present in amorphous form and being hydroxypropyl methylcellulose acetate succinate; and an intragranular blend comprising a bulking agent and / or filler, and a lubricant and / or glidant; an extragranular blend including a lubricant and / or a lubricant; The pharma- ceutically acceptable composition comprising:

36. Formula (I): 【Chemistry 14】 A pharma- ceutical acceptable composition for orally delivering 50 mg of a compound represented by the formula: a solid dispersion having 50 mg of the compound, the compound being present in amorphous form, the solid dispersion being hydroxypropyl methylcellulose acetate succinate; A bulking agent, A filler; and / or a lubricant, The pharma- ceutically acceptable composition.

37. Formula (I): 【Chemistry 15】 A pharma- ceutically acceptable tablet having 50 mg of a compound represented by the formula: An intragranular blend, comprising: a solid dispersion having 50 mg of a compound, the compound being present in amorphous form, the solid dispersion being hydroxypropyl methylcellulose acetate succinate; About 25-35% by weight of a bulking agent based on the total weight of the pharmaceutical composition; About 25-35% by weight of a filler, based on the total weight of the drug composition; and an extragranular blend comprising a lubricant and / or a lubricant. The pharma- ceutically acceptable tablet.

38. 38. The pharma- ceutically acceptable tablet of claim 37, wherein the filler is microcrystalline cellulose.

39. 39. A pharma- ceutically acceptable tablet according to claim 37 or 38, wherein the filler is lactose or a hydrate thereof.

40. Formula (I): 【Chemistry 16】 A pharma- ceutically acceptable tablet having 50 mg of a compound represented by the formula: wherein the tablet is a solid dispersion having 50 mg of the compound, wherein the compound is present in amorphous form, the solid dispersion being hydroxypropyl methylcellulose acetate succinate; About 25-35% by weight of microcrystalline cellulose, based on the total weight of the tablet; About 25-35% by weight of lactose or its hydrate, based on the total weight of the pharmaceutical composition; The pharma- ceutically acceptable tablet comprising:

41. 41. The pharma- ceutically acceptable tablet of claim 40, further comprising at least one of magnesium stearate, crospovidone, and silicon dioxide.

42. 42. The pharma- ceutically acceptable tablet of claim 40 or 41, wherein the tablet disintegrates in less than 1 minute when tested using USP <701> for an uncoated tablet.

43. Formula (I): 【Chemistry 17】 A pharma- ceutical acceptable composition for orally delivering 50 mg of a compound represented by the formula: An intragranular blend, comprising: a solid dispersion having 50 mg of the compound, the compound being present in amorphous form, the solid dispersion being hydroxypropyl methylcellulose acetate succinate; About 25-35% by weight of microcrystalline cellulose based on the total weight of the pharmaceutical composition; About 25-35% by weight of lactose or its hydrate based on the total amount of the pharmaceutical composition; About 5% by weight of crospovidone based on the total weight of the pharmaceutical composition; About 0.5% by weight of silicon dioxide based on the total amount of the composition of the drug; About 0.5% by weight of magnesium stearate based on the total weight of the pharmaceutical composition; (ii) an extragranular blend comprising about 0.5% by weight of silicon dioxide based on the total weight of the pharmaceutical composition; and (iii) about 0.5% by weight of magnesium stearate based on the total weight of the pharmaceutical composition. The pharma- ceutically acceptable composition comprising:

44. 44. The pharma- ceutically acceptable composition or tablet of any one of claims 1 to 43, wherein the composition or tablet releases at least 80% of the compound after 10 to 40 minutes when the composition is tested using USP Apparatus II (Paddle Method) at 37°C in 900 mL sodium acetate buffer at pH 4.5 with a paddle speed of 75 rpm.

45. 45. The pharma- ceutically acceptable composition or tablet of any one of claims 1 to 44, wherein the composition or tablet releases at least 80% of the compound after 20 minutes when the composition is tested using USP Apparatus II (Paddle Method) at 37°C in 900 mL sodium acetate buffer at pH 4.5 with a paddle speed of 75 rpm.

46. In patients in need of treatment, the present invention relates to a gastrointestinal stromal tumor (GIST), NF-1-deficient gastrointestinal stromal tumor, succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor, KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor, melanoma, acute myeloid leukemia, germ cell tumors of seminoma or dysgerminoma, mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, pediatric neuroendocrinology, and the like.

43. A method for treating a disease selected from the group consisting of hepatoma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, and non-small cell lung cancer, comprising administering to said patient a therapeutically effective amount of said composition or one or more of the tablets of claims 1-42.

47. 46. ​​A method for treating a disease selected from the group consisting of gastrointestinal stromal tumor (GIST), KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor, lung cancer, glioblastoma, glioma, malignant peripheral nerve sheath sarcoma, and hypereosinophilic syndrome, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the composition or one or more tablets according to claims 1-45.

48. 46. ​​A method of treating a disease selected from the group consisting of KIT-driven germ cell tumors (e.g., testicular germ cell), KIT-driven skin cancer, or KIT-driven renal cell carcinoma in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the composition or one or more of the tablets of claims 1-45.

49. Also provided herein, in another embodiment, is a method of treating a disease selected from the group consisting of penile cancer, PDGFRA-driven penile cancer, prostate cancer, PDGFRA-driven prostate cancer, PDGFRA-driven non-melanoma skin cancer, PDGFRA-driven glioma, PDGFRA-driven sarcoma, PDGFRA-driven glioblastoma, or PDGFRA-driven pancreatic cancer, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the composition or one or more tablets of claims 1-45.

50. 46. ​​A method of treating a disease comprising a mutation selected from the group consisting of vaginal cancer, prostate cancer, penile cancer, non-melanoma skin cancer, melanoma, or breast sarcoma in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of one or more of the compositions or tablets of claims 1-45, wherein said disease comprises a PDGFRAB mutation.

51. 47. The method of claim 46, wherein the disease is gastrointestinal stromal tumor (GIST).

52. Gastrointestinal stromal tumor (GIST), KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor, melanoma, acute myeloid leukemia, seminoma or germ cell tumors such as dysgerminoma 46. ​​Use of a composition or tablet as claimed in any one of claims 1 to 45, wherein there is provided use of a composition or tablet as described herein for the preparation of a medicament for treating a disease selected from the group consisting of: mastocytosis, mast cell leukemia, lung adenocarcinoma, lung squamous cell carcinoma, glioblastoma, glioma, childhood glioma, astrocytoma, sarcoma, malignant peripheral nerve sheath sarcoma, intimal sarcoma, eosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilic acute myeloid leukemia, lymphoblastic T-cell lymphoma, non-small cell lung cancer.

53. 53. Use of the composition of claim 52 for the preparation of a medicament for the treatment of a disease selected from the group consisting of gastrointestinal stromal tumor (GIST), KIT-driven gastrointestinal stromal tumor, PDGFRA-driven gastrointestinal stromal tumor, lung cancer, glioblastoma, glioma, malignant peripheral nerve sheath sarcoma, and hypereosinophilic syndrome.

54. 50. The use according to claim 49, wherein the disease is gastrointestinal stromal tumor (GIST).

55. The method or use according to any one of claims 46 to 54, wherein the disease is caused by the kinase activity of c-KIT and / or PDGFRA, and / or oncogenic forms thereof.

56. The compound of formula (I) according to any one of claims 1 to 37 【Chemistry 18】 1. A process for the preparation of a solid dispersion comprising an amorphous form of a compound of The process comprising: (a) mixing a compound of formula (I), a solvent, the polymer, and water to obtain a suspension; (b) optionally stirring and / or mixing the final suspension while maintaining a temperature of about 10-25° C.; (c) passing the suspension through an in-line heat exchanger to dissolve the suspended particles prior to introduction into the spray dryer; (d) spray drying the suspension to obtain a spray-dried dispersion; (e) drying the spray-dried dispersion, thereby obtaining the solid dispersion.

57. 57. The process of claim 56, wherein heating comprises passing the suspension through an in-line heat exchanger.

58. 57. A compound of formula (I) produced by the process of claim 55 or 56 【Chemistry 19】 A solid dispersion comprising an amorphous form of the compound of formula (I).

Images